### Title Page

Relationship between body regional fat and cardiovascular disease in middle-aged and young

adults: Results from NHANES 2011-2018 and Mendelian randomization meta-analysis

Zheng Liu<sup>1</sup> MD, Wenqi Shu<sup>1</sup> MD, Meisi Liu MD<sup>1</sup>, Wei Chong Prof.<sup>1</sup>

Author affiliations: 1: The First Hospital of China Medical University, Shenyang, China

Short title: Body Regional Fat & CVD in Middle-Aged & Young

Correspondent Author: Wei Chong

Email: <u>wchong@cmu.edu.cn</u>

Postal address:

The First Hospital of China Medical University,

No. 155, Nanjing North Street, Heping District,

Shenyang, China

Postal Code: 11001

Word count: 7307

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### ABSTRACT

#### BACKGROUND:

To assess the correlation between regional body fat and cardiovascular diseases in middle-aged and young adults.

#### METHODS:

Information on the regional body fat, including the mass and percentage of fat in the head, arms, trunk, and legs, was collected. Data for the observational study were derived from the National Health and Nutrition Examination Survey 2011–2018. The relationship between exposure and outcomes was primarily assessed using restricted cubic splines (RCS), weighted multivariable logistic regression, and subgroup analysis. In the Mendelian randomization (MR) analysis, the outcome was precisely defined as coronary heart disease (CHD), and the data primarily originated from the IEU OpenGWAS project.

#### **RESULTS:**

A total of 10,158 participants aged 20–59 years were included, with a prevalence of cardiovascular diseases at 3.4%. Regional body fat was primarily associated with heart disease rather than with stroke. The RCS indicated a positive linear correlation between all body fat masses and the percentage of heart disease. After adjusting for confounding factors, logistic regression analysis revealed significant associations between heart disease and head fat mass (unit: 0.1 kg, odds ratio [OR] = 1.31, p = 0.002), head fat percentage (unit: 1%, OR = 1.37, p = 0.018), arm fat mass (unit: 1 kg, OR = 1.18, p = 0.047), and trunk fat mass (unit: 2.5 kg, OR = 1.14, p = 0.027). Leg fat mass and

3

percentage of fat in the arms, trunk, and legs showed no significant correlation with heart disease (p > 0.05). The IEU OpenGWAS database does not include head-fat information. MR meta-analysis indicated that the fat mass and percentage in the arms, trunk, and legs were all causally related to CHD.

### **CONCLUSION:**

Head fat mass, head fat percentage, arm fat mass, and trunk fat mass were all associated with heart disease and were likely causally related.

### **KEY WORDS**

head fat, arm fat, trunk fat, leg fat, cardiovascular disease, heart disease

## WHAT IS KNOWN

Trunk fat mass is positively associated with certain cardiovascular risk factors, while leg fat mass is the opposite.

Dual-Energy X-ray Absorptiometry measures regional body fat, characterized by its speed, low radiation exposure, and cost-effectiveness, making it suitable for community settings.

# WHAT THE STUDY ADDS

In middle-aged and young adults, regional body fat mass and percentage are not associated with stroke.

Head fat mass, head fat percentage, arm fat mass, and trunk fat mass are all associated with heart disease and are likely causally related.

Measurement of fat in the head, arms, and trunk may contribute to early screening for

heart diseases in middle-aged and young adults.

# Non-standard Abbreviations and Acronyms

- NHANES National Health and Nutrition Examination Survey
- CVD cardiovascular disease
- CHD coronary heart disease
- MR mendelian randomization
- SNPs Single Nucleotide Polymorphisms
- DXA Dual-Energy X-ray Absorptiometry
- RFM regional fat mass
- HFM head fat mass
- AFM arm fat mass
- TFM trunk fat mass
- LFM leg fat mass
- RFP regional fat percentage
- HFP head fat percentage
- AFP arm fat percentage
- TFP trunk fat percentage
- LFP leg fat percentage
- RCS restricted cubic splines
- MCQ medical conditions questionnaire
- BMI body mass index

5

- IVW inverse variance-weighted
- PIR poverty income ratio
- OR odds ratio

#### INTRODUCTION

Cardiovascular Disease (CVD) is a major cause of death and disease burden among residents in many countries worldwide, and the problem of premature death is becoming increasingly severe in many regions<sup>1-4</sup>. The United Nations member states hope to reduce the premature death rate of CVD by 25% by 2025<sup>5</sup>; however, it is difficult for all regions to achieve this goal<sup>6</sup>. Exploring the risk factors for CVD onset in middle-aged and young adults to facilitate early screening and timely intervention can help reduce the incidence and premature mortality in this population.

The distribution of fat in different regions is associated with various health risks. Early research found that trunk fat mass (TFM) and leg fat mass (LFM) are associated with certain risk factors for CVD<sup>7-10</sup>. These include metabolic syndrome<sup>11,12</sup>, insulin resistance<sup>13,14</sup>, hypertension<sup>15</sup>, and risk of systemic inflammation<sup>16</sup>, although the mechanisms are not yet fully understood. Most studies consider TFM to be a risk factor and LFM to be a protective factor, which has been confirmed in adolescents<sup>17-19</sup>, <sup>16,20</sup>, and older adults<sup>21,22</sup>. However, these studies were observational and lacked causal inferences. There has been no research to confirm whether TFM and LFM truly influence the occurrence of CVD or to assess their potential as risk screening indicators for CVD,

particularly in middle-aged and young adult populations. Body regional fat includes head fat mass (HFM) and arm fat mass (AFM); however, few studies have focused on HFM and AFM. Regional body fat was measured using Dual-Energy X-ray Absorptiometry (DXA). DXA is characterized by speed, ease of use, and low radiation exposure, making it suitable for primary care or physical examination settings.

The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional survey based on a stratified population across the United States that provides a large-sample, nationally representative, and high-quality data. To date, no systematic study has been conducted on body regional fat mass (RFM) information in the NHANES 2011–2018. Mendelian randomization (MR) analysis is a tool that utilizes genetic data to analyze the causal relationship between exposure factors and outcomes<sup>23</sup>, with a lower risk of confounding bias and reverse causation<sup>24</sup>. Therefore, MR is considered a complementary method to randomized controlled trials, effectively serving as a strong supplement to observational studies.

The study design was depicted in **Figure 1.** In this study, we combined a large observational study from NHANES from 2011–2018 with an MR meta-analysis to comprehensively evaluate the relationship between body RFM (including HFM, AFM, TFM, and LFM) and CVD in middle-aged and young adult populations. Furthermore, we also analyzed the relationship between body regional fat percentage (RFP) and CVD.

7

### METHODS

### Cross-sectional study design

### Study population

This study extracted population data from four cycles of the NHANES 2011-2018, as other cycles did not contain information on RFM and RFP. In the NHANES, the age distribution of the population undergoing RFM and RFP measurements ranged from 8 to 59 years. After excluding individuals with missing information on the main exposure factors and outcome indicators, the age distribution of the population was concentrated between 20 and 59 years old. Therefore, this study focused on the middle-aged and young adult populations. All participants in the NHANES provided informed consent, and the information was publicly anonymized and authorized by the NCHS Ethics Review Committee.

### Definition and extraction of body RFM, RFP, and CVD

The measurement of RFM and RFP was conducted using DXA. RFM included HFM, AFM, TFM, and LFM, with the original units in grams (g). RFP included head fat percentage (HFP), arm fat percentage (AFP), trunk fat percentage (TFP), and leg fat percentage (LFP). DXA measurements excluded individuals who were pregnant, weighed more than 450 pounds, or were taller than six feet five inches.

In this study, data on CVD were extracted from the Medical Conditions Questionnaire (MCQ) module in the NHANES, where MCQ information was obtained through personal interviews. In this study, CVD was defined to include congestive heart failure, coronary

8

heart disease, angina, heart attack, and stroke, with the corresponding variables in MCQ being MCQ160B, MCQ160C, MCQ160D, MCQ160E, and MCQ160F. CVD includes other diseases as well, but owing to the lack of related information in the NHANES, CVD in this study was defined based on the aforementioned diseases.

### **Definition of covariates**

The main covariates in this study were age, sex, race, educational level, poverty level, smoking status, body mass index (BMI), obesity, diabetes, hypertension, and dyslipidemia. Smoking was defined as the smoking of at least 100 cigarettes per day. Obesity was defined as a BMI  $\geq$  28. Diabetes was defined based on a history of diabetes, hemoglobin A1c level  $\geq$  6.5%, or a fasting blood glucose level  $\geq$  126 mg/dL. Hypertension was defined based on a history of hypertension, the use of antihypertensive medication, or having a systolic blood pressure  $\geq$  140 mmHg or diastolic blood pressure  $\geq$  90 mmHg on at least 3 days in the examination module. Dyslipidemia included a history of lipid disorder, total cholesterol  $\geq$  6.2 mmol/L, non-high-density lipoprotein  $\geq$  4.9 mmol/L, and triglycerides  $\geq$  2.3 mmol/L, with any one of these criteria being met.

#### Statistical analysis

Continuous variables were presented as medians (IQR), while categorical variables were presented as n (%). The chi-square test with Rao & Scott's second-order correction and the Wilcoxon rank-sum test were used for complex survey samples. Baseline

9

investigations were conducted using CVD and RFM as separate outcomes. CVD was categorized as heart disease or stroke, and RFM was stratified into quartiles (Q1 to Q4). Pearson's correlation coefficient analysis was conducted to examine the correlation between different RFMs in the body. Restricted cubic splines (RCS) were used to assess the linear relationship between exposure and outcome. Three logistic regression models were established to analyze the association between exposure and outcomes. The first model was unadjusted, the second model was further adjusted for age, sex, and race, and the third model was additionally adjusted for education, poverty level, BMI, and smoking. In the logistic regression analysis, the units of RFM were readjusted as follows: HFM to 0.1 kg, AFM to kg, TFM to 2.5 kg, and LFM to kg. Subgroup analyses were conducted based on sex, age, poverty level, smoking status, obesity, hypertension, diabetes, and dyslipidemia, and the interactions between exposure and subgroups were analyzed.

In this study, important variables with missing values were excluded, and no imputation was performed. All analyses of NHANES data were weighted to account for the complex sampling design. In this study, the minimum sample weight used was the MEC examination weight spanning four cycles. The weight variable was defined as 1/4WTMEC2YR. All statistical analyses were performed using R version 4.1.3 (The R Foundation for Statistical Computing, Vienna, Austria), with the significance level set at 0.05.

#### MR meta-analysis

Based on the results of the cross-sectional study, exposure in the MR analysis was defined as RFM and RFP, and the outcome was defined as coronary heart disease (CHD), with data primarily sourced from the IEU OpenGWAS project. Initially, a two-sample MR analysis was conducted, in which the selected instrumental variables (Single Nucleotide Polymorphisms, SNPs) had to meet the following criteria: 1) genome-wide significance level (P <  $5 \times 10^{-8}$ ); 2) not in linkage disequilibrium (r2 < 0.001, 10,000 kb); and 3) not a weak instrumental variable (F-statistic > 10). Five methods were used to determine the causal relationship between exposure and outcome: inverse variance-weighted (IVW), MR-Egger, weighted median, simple mode, and weighted mode. Among these, the IVW was the primary method, and secondary methods were used to evaluate the robustness of the IVW results. Heterogeneity was assessed using IVW and MR-Egger tests, and pleiotropy was evaluated using the MR-Egger intercept test. A sensitivity analysis was conducted using the leave-one-out method and funnel plots. The criteria for inclusion in the MR meta-analysis were that the odds ratio (OR) values from all five MR analysis methods were consistent in direction and that there was no horizontal pleiotropy. The MR meta-analysis was based on the IVW results. If there was heterogeneity in the statistical results, a random-effects model was used, and if there was no heterogeneity, a fixed-effects model was used.

#### RESULTS

#### NHANES population characteristics and baseline features

11

In total, 10,158 participants were included in this study, comprising 52% males and 48% females, with an average age of 39 years. In the weighted analysis, CVD accounted for 2.8%, heart disease for 2.1%, and stroke for 1.0%. As shown in **Table 1**, except for LFM and LFP, patients with CVD and heart disease had significantly higher HFM, AFM, TFM, HFP, AFP, and TFP values. Patients who experienced a stroke did not show differences in body RFM and RFP, with only AFP being slightly higher (24.07% vs. 24.29%, p = 0.003). Upon further dividing RFM into quartiles (Q1–Q4) for the outcome, it was observed that CVD and heart disease significantly increased with an increase in HFM, AFM, and TFM, while no difference was observed in LFM. Stroke patients with stroke showed a significant difference only in AFM (p = 0.022). This information can be found in (**TableS1-TableS4**). AFM, TFM, and LFM exhibited very strong positive correlations, and HFM showed a positive correlation with these three variables; however, the correlation was relatively weaker (**Table 2**).

#### The relationship between RFM and RFP with heart disease in NHANES

As shown in **Figure 2**, the RCS indicated a positive linear correlation between heart disease and all four types of body RFM and RFP. **Table 3** shows the relationship between the four types of body RFM and RFP with heart disease under three models. Body RFM, HFM, AFM, and TFM showed consistent results across all three models. For every 0.1 kg increase in HFM, the risk of heart disease increased by 31% (OR = 1.31, 95% CI: 1.11–1.54, p = 0.002, Model 3). For every 1 kg increase in AFM, the risk of heart disease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease in Crease in AFM, the risk of heart disease increased by 18% (OR = 1.18, 95% CI: 1.00–1.38, p = 0.047, Model 3). For every

12

2.5 kg increase in TFM, the risk of heart disease increased by 14% (OR = 1.14, 95% CI: 1.02–1.28, p = 0.027, Model 3). LFM was not significantly associated with heart disease in any of the three models. In terms of body RFP, only HFP showed consistent and significant results across all three models. For every 1% increase in HFP, the risk of heart disease increased by 37% (OR = 1.37, 95% CI: 1.06 –1.77, p = 0.018, Model 3). AFP and TFP were non-significant in Model 3, and LFP was not significant in any of the models.

The results of the subgroup analysis are shown in **Figure 3**. Interaction with the poverty income ratio (PIR) was present in all four types of RFM and RFP, hypertension interacted with AFM and TFM, and dyslipidemia interacted with AFM, TFM, LFM, TFP, and LFP. In the subgroup analyses, HFP showed the most consistent performance, whereas the associations of the rest of the RFM and RFP with heart disease weakened in some subgroups.

#### MR meta-analysis

No studies on HFM or HFP have been published in the IEU OpenGWAS databases. For AFM, LFM, AFP, and LFP, 12 studies each were identified, and for TFM and TFP, six studies each were found. After screening the SNPs, four studies on AFM, LFM, AFP, and LFP and two studies on TFM and TFP met the criteria. Based on the results of the observational study, we chose CHD as the exposure source and identified six studies in the IEU OpenGWAS database. The results of each MR analysis are detailed in the **TableS5 to TableS10**. Heterogeneity was present in all MR meta-analyses in this study

13

(p < 0.05); hence, all were based on random effects models. The MR meta-analysis results showed a causal relationship between AFM and CHD (OR = 1.174, 95% CI: 1.092-1.261, p < 0.001), between TFM and CHD (OR = 1.084, 95% CI: 1.022-1.149, p = 0.007), between LFM and CHD (OR = 1.161, 95% CI: 1.083-1.245, p < 0.001), between AFP and CHD (OR = 1.260, 95% CI: 1.139–1.134, p < 0.001), between TFP and CHD (OR = 1.170, 95% CI: 1.044–1.310, p = 0.007), and between LFP and CHD (OR = 1.237, 95% CI: 1.119 - 1.367, p < 0.001).

#### DISCUSSION

This study explored, for the first time, the relationship between regional body fat and CVD in the middle-aged and young populations using data from the NHANES 2011–2018 and MR meta-analysis. An observational study showed that HFM, AFM, TFM, and HFP were significantly associated with heart disease, whereas AFP and TFP had a weaker association, and LFM and LFP had no association with heart disease. An observational study also found that regional body fat was not associated with stroke. As the primary heart disease in the observational study was CHD, the MR meta-analysis selected CHD as the outcome and confirmed the causal relationship between AFM, TFM, AFP, and TFP and CHD. However, the MR meta-analysis results for LFM and LFP were inconsistent with those of observational studies. Owing to a lack of data, MR analyses of HFM and HFP were not conducted. The findings of this study are important for early screening and prevention of heart disease in middle-aged and young individuals. The detection of body regional fat is characterized by low cost, low radiation exposure,

convenience, and speed, making it suitable for screening in the community. By focusing on fat accumulation in specific body regions, doctors may be able to identify high-risk individuals more accurately and implement targeted intervention measures.

Regional body fat refers to the fat accumulated in specific areas of the body. It can accurately differentiate between fat and nonfat tissues (such as muscles), providing detailed information about fat distribution. The distribution of fat in different regions is associated with various health risks; hence, regional body fat offers a more comprehensive health assessment. Previous studies have discovered associations between TFM, LFM, and certain cardiovascular health factors, which inspired the scientific hypothesis for this study. Notably, the previously understudied HFM and HFP levels were identified as significant risk factors for heart disease. Based on the results of the baseline analysis, stroke, whether as an outcome or a contributing factor, showed no significant correlation with fat in any of the four body regions (Table1. **TableS1-TableS4**) . Therefore, in subsequent studies, we specifically refined the outcomes of CVD to include heart disease. This study aimed to determine the strength of the causal relationship between regional body fat and heart disease to aid in early screening of heart disease. We did not intend to prove this to be an independent risk factor. Therefore, excessive confounding factors such as hypertension, dyslipidemia, and diabetes were not adjusted for. Instead, a subgroup analysis was used as a substitute. Next, we discuss the results of head fat, arm fat, trunk fat, and leg fat in this study in

sequence.

Previous studies, which are few in number on head fat, have found that the accumulation of head fat is closely related to dyslipidemia and hyperuricemia<sup>25</sup>, consistent with the results of this study. The baseline survey in this study showed that an increase in HFM was not only associated with heart disease, but also significantly correlated with hypertension, dyslipidemia, and diabetes (TableS1). While there is currently limited research on head fat, we believe that it affects the occurrence of CHD by influencing certain cardiovascular risk factors, similar to trunk fat. In this study, after adjustment, HFM and HFP were not only the most stable among all indicators but were also the most clinically significant (Table3). In all subgroup analyses of the PIR, there was evidence of an interaction, which was an interesting finding. This suggests that differences in socioeconomic status may lead to variations in various lifestyles and health behaviors, potentially influencing the risk of heart disease. The association between HFM and heart disease weakened in some subgroups, possibly because other risk factors present in these subgroups diminished the effect of HFM. However, HFP showed stable performance across all subgroups. Unfortunately, there have been no studies on HFM and HFP in GWAS databases. However, by combining observational studies with MR meta-analyses of other regional fats, we believe that head fat, especially HFP, has great potential as a screening indicator for heart disease risk.

Although both are limb fats, compared to leg fat, there are fewer studies on arm fat and its association with health risks, and the findings are contradictory. Sánchez et al.'s cross-sectional study of 683 university students aged 18-30 found no association between arm fat and risk factors such as dyslipidemia, insulin resistance, and hypertension<sup>26</sup>. In a study of 9,930 middle-aged and older individuals, Shi et al. found that mid-upper arm circumference was positively correlated with metabolic syndrome<sup>27</sup>. Gavi et al. found a negative correlation between the limb fat-to-trunk fat ratio (LFM/TFM) and insulin resistance risk in older adults <sup>28</sup>, whereas Travis et al. found no association between LFM/TFM and any markers of cardiovascular metabolic risk in older individuals<sup>21</sup>. However, it is important to note that both of these studies had relatively small sample sizes, with 38 participants in the former and 136 in the latter, and did not differentiate between arm and leg fat but instead studied limb fat collectively. Leg fat is traditionally recognized as a protective factor for health and combining arm fat and leg fat with limb fat is inappropriate. The baseline survey of this study revealed a significant association between the occurrence of heart disease and high AFM and AFP (Table1). High AFM was significantly associated with heart disease and cardiovascular risk factors (TableS2), as indicated by the RCS curves, which showed a clear positive linear correlation (Figure2B, 2F). In further logistic regression and subgroup analyses, AFM performance remained stable, whereas AFP levels showed weaker statistical and clinical significance. MR meta-analysis further confirmed the causal relationship between AFM and CHD (Figure 4B). Therefore, we believe that AFM is a risk factor for heart disease

and has clinical value in risk screening.

As mentioned earlier, previous studies have generally considered TFM as a health risk factor, whereas LFM is a protective factor. These health risks include metabolic syndrome, insulin resistance, high blood pressure, and overall risk of inflammation, among others. However, there has been limited research analyzing CVD or heart disease as endpoints. Trunk fat accumulates primarily in the chest, abdomen, and back. Its composition and effects on health are complex, and encompass the influence of both visceral and subcutaneous fat. However, the underlying mechanisms are not well understood. Current research suggests that visceral fat in the trunk region secretes more free fatty acids<sup>29,30</sup> but has reduced adiponectin expression and secretion rates<sup>31-34</sup>, leading to insulin resistance<sup>35,36</sup>, concentric left ventricular remodeling<sup>37</sup>, and left atrial dysfunction<sup>38</sup>. Deep subcutaneous fat in the trunk exhibits a phenotype similar to that of visceral fat, whereas superficial subcutaneous fat in the legs possesses stronger metabolic characteristics<sup>39-41</sup>. The results of this study are consistent with those of previous studies showing a significant association between increased TFM and both cardiovascular risk factors and CHD (TableS3). After logistic regression, subgroup analysis, and MR meta-analysis, the performance of the TFM remained consistently stable, with a weakened association with the outcomes observed only in two subgroups: PIR<1 and high blood pressure. Although TFP also demonstrated a causal relationship in the MR meta-analysis, it showed moderate performance in logistic regression analysis

and had limited clinical significance **(Table3).** Thus, we believe that TFM is a risk factor for heart disease and has a clinical value in risk screening.

Previous studies have commonly regarded leg fat as a protective factor against cardiovascular risk; however, this study did not find an association between leg fat and CVD or heart disease. Indeed, RCS and MR meta-analyses suggested that leg fat is a risk factor for heart disease. First, from the baseline survey, it is evident that different RFMs in the body are positively correlated. With an increase in the LFM, the other RFMs also increase (TableS1-TableS4). The Pearson correlation coefficient revealed that LFM was strongly correlated with AFM and TFM, but weakly correlated with HFM (Table2). The protective effect of leg fat may be overshadowed by risk effects in other regions. This could also explain why the results of the RCS and MR meta-analyses indicate that LFM is a risk factor for heart disease. Correcting for other RFMs before analyzing the relationship between LFM and heart disease was not the aim of this study, and it has no practical significance for the risk assessment of heart disease. Second, previous studies did not focus on the disease itself as the endpoint but rather on risk factors such as dyslipidemia<sup>26,42</sup>, insulin resistance<sup>43-45</sup>, cardiometabolic functions<sup>19,46,47</sup>, and inflammatory markers<sup>16</sup>. Leg fat itself may not be a suitable risk indicator for CVD; it merely affects the upstream indicators of CVD, which was the aim of this study. Third, most previous studies focused on the ratio of trunk to leg fat, not on leg fat alone <sup>19,20,42,44,46,47</sup>. This study was an independent investigation of fat in various regions of the body. Fourth, although

19

leg fat has been shown to be beneficial for some aspects of cardiovascular health, the population with high LFM in this study was more prone to obesity, hypertension, and even diabetes (**TableS4**). However, whether these risk factors are associated with LFM remains unclear. This could also explain why LFM appeared to be a risk factor for heart disease in the RCS and MR meta-analyses as these two analyses did not adequately adjust for confounding factors. Finally, the study population consisted of middle-aged and young adults aged 20–59 years, which differed from the populations studied in previous studies. With advancing age, there are changes in fat distribution patterns. Older adults often experience a loss of fat in their limbs and an increase in abdominal fat. Therefore, leg fat may be more important in older individuals than in middle-aged or young adults. In conclusion, we believe that LFM has no value in risk screening for heart disease, and further research is needed to explore its relationship with cardiovascular health.

This study utilized nationally representative data and an MR meta-analysis, making it the first comprehensive analysis of the relationship between regional body fat and heart disease. This is the first study to target middle-aged and young adults. Overall, based on the results of logistic regression, HFM, HFP, AFM, and TFM were all correlated with heart disease, with only a slight decrease in correlation in some subgroups. Currently, there is very little research on head fat, and in our study, it was a highly promising indicator. Specifically, for every 0.1 kg increase in HFM, the risk of heart disease

20

increased by 31%, whereas for every 1% increase in HFP, the risk of heart disease increased by 37% (Table3). HFP exhibited even more stable performance in the subgroup analysis. In Pearson correlation analysis, the correlation between head fat and fat in other regions was not strong (Table2), indicating that the influence of head fat on heart disease was relatively independent of other regions. Unfortunately, there is no information on HFM and HFP in the IEU OpenGWAS project, leading to a lack of MR meta-analyses specifically for head fat. However, by combining MR analysis with other RFMs, we believe there is a strong likelihood of a causal relationship between head fat and heart disease. The primary aim of this study was to establish the correlation between regional body fat and cardiovascular diseases in middle-aged and young adults, with the goal of providing a basis for the early screening of cardiovascular diseases in this population. Measurement of regional fat is convenient, economical, and low in radiation, making it suitable for community-based settings.

This study had certain limitations. First, in conducting the correlation analysis, we did not consider the mutual influence between different RFMs because this was not the primary focus of this study. This study aimed to analyze the relationship between body RFMs and heart disease to understand which RFM would be suitable as screening indicators for heart disease in the real world. Second, the MR analysis in this study was not solely focused on middle-aged and young adults; hence, the population characteristics did not fully match those of observational studies. Third, when conducting an MR analysis, it

is generally preferred to have different populations for exposure and outcomes. However, due to the scarcity of relevant studies, we included all studies from the IEU OpenGWAS for analysis. In this study, the MR analysis, serving as a supplementary analysis to observational studies, could not conclusively prove causality but offered substantial potential.

#### CONCLUSIONS

In conclusion, we believe that HFM, HFP, AFM, and TFM are risk factors for the onset of heart disease in middle-aged and young adults, and that there may be a causal relationship. Our study may provide new references for the early screening and intervention of heart disease in the middle-aged and young population.

### ACKNOWLEDGMENTS

None

### SOURCES OF FUNDING

The funding for this study was provided by the Central Guiding Local Science and Technology Development Fund of Liaoning Province, China. The project is titled "Construction Research on Public Cardiovascular and Cerebrovascular Emergency Sudden Death Prevention and Treatment System Based on Intelligent Emergency Platform." Project Number: 2023JH6/100200001.

### DISCLOSURES

22

None

### SUPPLEMENTAL MATERIAL

TableS1-TableS10

### REFERENCES

- 1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A. Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646. doi: 10.1161/cir.0000000000000678
- 2. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nature reviews Cardiology. 2019;16:203-212. doi: 10.1038/s41569-018-0119-4
- 3. Turk-Adawi K, Sarrafzadegan N, Fadhil I, Taubert K, Sadeghi M, Wenger NK, Tan NS, Grace SL. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nature reviews Cardiology. 2018:15:106-119. doi: 10.1038/nrcardio.2017.138
- 4. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016;37:2315-2381. doi: 10.1093/eurheartj/ehw106
- 5. Sacco RL, Roth GA, Reddy KS, Arnett DK, Bonita R, Gaziano TA, Heidenreich PA, Huffman MD, Mayosi BM, Mendis S, et al. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation. Circulation. 2016;133:e674-690. doi: 10.1161/cir.000000000000395
- 6. Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, Murray CJ. Estimates of global and regional premature cardiovascular mortality in 2025. Circulation. 2015;132:1270-1282. doi: 10.1161/circulationaha.115.016021
- 7. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis (Dallas, Tex). 1990;10:497-511. doi: 10.1161/01.atv.10.4.497
- 8. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, Buchan I, Day N, Khaw KT. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation. 2007;116:2933-2943. doi: 10.1161/circulationaha.106.673756
- 9. Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. International journal of

cardiology. 2013;169:166-176. doi: 10.1016/j.ijcard.2013.08.077

- 10. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine reviews. 2000;21:697-738. doi: 10.1210/edrv.21.6.0415
- 11. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887. doi: 10.1038/nature05488
- 12. Zhang X, Hu EA, Wu H, Malik V, Sun Q. Associations of leg fat accumulation with adiposity-related biological factors and risk of metabolic syndrome. Obesity (Silver Spring, Md). 2013;21:824-830. doi: 10.1002/oby.20028
- 13. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE, Manson JE. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. American journal of epidemiology. 1997;145:614-619. doi. 10.1093/oxfordjournals.aje.a009158
- 14. Yang L, Deng H, Pan W, Huang X, Xu K, Zhang X, Hu X, Gu X. The Inverse Association of Leg Fat Mass and Osteoporosis in Individuals with Type 2 Diabetes Independent of Lean Mass. Diabetes, metabolic syndrome and obesity : targets and therapy. 2022;15:1321-1330. doi: 10.2147/dmso.S358717
- 15. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY. Visceral adiposity and the prevalence of hypertension in Japanese Americans. Circulation. 2003;108:1718-1723. doi: 10.1161/01.Cir.0000087597.59169.8d
- 16. Wu H, Qi Q, Yu Z, Sun Q, Wang J, Franco OH, Sun L, Li H, Liu Y, Hu FB, et al. Independent and opposite associations of trunk and leg fat depots with adipokines, inflammatory markers, and metabolic syndrome in middle-aged and older Chinese men and women. The Journal of clinical endocrinology and metabolism. 2010;95:4389-4398. doi: 10.1210/jc.2010-0181
- Barbour-Tuck EN, Erlandson MC, Sherar LB, Eisenmann JC, Muhajarine N, Foulds H, Vatanparast 17. H, Nisbet C, Kontulainen S, Baxter-Jones ADG. Relationship Between Trajectories of Trunk Fat Development in Emerging Adulthood and Cardiometabolic Risk at 36 Years of Age. Obesity (Silver Spring, Md). 2019;27:1652-1660. doi: 10.1002/oby.22576
- 18. He Q, Zhang X, He S, Gong L, Sun Y, Heshka S, Deckelbaum RJ, Gallagher D. Higher insulin, triglycerides, and blood pressure with greater trunk fat in Tanner 1 Chinese. Obesity (Silver Spring, Md). 2007;15:1004-1011. doi: 10.1038/oby.2007.599
- 19. Cioffi CE, Alvarez JA, Welsh JA, Vos MB. Truncal-to-leg fat ratio and cardiometabolic disease risk factors in US adolescents: NHANES 2003-2006. Pediatric obesity. 2019;14:e12509. doi: 10.1111/ijpo.12509
- 20. Han E, Cho NH, Kim MK, Kim HS. Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011). Diabetes & metabolism journal. 2019;43:461-473. doi: 10.4093/dmj.2018.0081
- 21. Saunders TJ, Davidson LE, Janiszewski PM, Després JP, Hudson R, Ross R. Associations of the limb fat to trunk fat ratio with markers of cardiometabolic risk in elderly men and women. The journals of gerontology Series A, Biological sciences and medical sciences. 2009;64:1066-1070. doi: 10.1093/gerona/glp079
- 22. Kim JH, Chon J, Soh Y, Han YR, Won CW, Lee SA. Trunk fat mass correlates with balance and

24

physical performance in a community-dwelling elderly population: Results from the Korean Frailty and cohort study. Medicine (Baltimore). 2020;99:e19245. doi: aging 10.1097/md.000000000019245

- 23. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? International journal of epidemiology. 2003;32:1-22. doi: 10.1093/ije/dyg070
- 24. Smith GD, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology Mendelian randomization. 2008:40:524-541. through Annals of medicine. doi: 10.1080/07853890802010709
- 25. Wang XC, Liu H, Huang YY, Sun H, Bu L, Qu S. Head fat is a novel method of measuring metabolic disorder in Chinese obese patients. Lipids in health and disease. 2014;13:113. doi: 10.1186/1476-511x-13-113
- 26. Sánchez-López M, Ortega FB, Moya-Martínez P, López-Martínez S, Ortiz-Galeano I, Gómez-Marcos MA, Sjöström M, Martínez-Vizcaíno V. Leg fat might be more protective than arm fat in relation to lipid profile. European journal of nutrition. 2013;52:489-495. doi: 10.1007/s00394-012-0350-4
- 27. Shi J, Yang Z, Niu Y, Zhang W, Li X, Zhang H, Lin N, Gu H, Wen J, Ning G, et al. Large mid-upper arm circumference is associated with metabolic syndrome in middle-aged and elderly individuals: a community-based study. BMC Endocr Disord. 2020;20:78. doi: 10.1186/s12902-020-00559-8
- 28. Gavi S, Feiner JJ, Melendez MM, Mynarcik DC, Gelato MC, McNurlan MA. Limb fat to trunk fat ratio in elderly persons is a strong determinant of insulin resistance and adiponectin levels. The journals of gerontology Series A, Biological sciences and medical sciences. 2007;62:997-1001. doi: 10.1093/gerona/62.9.997
- 29. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. *Diabetes/metabolism research* and reviews. 2002;18 Suppl 2:S5-9. doi: 10.1002/dmrr.254
- 30. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiological reviews. 1994;74:761-811. doi: 10.1152/physrev.1994.74.4.761
- 31. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. International journal of obesity (2005). 2010;34:949-959. doi: 10.1038/ijo.2009.286
- 32. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. The Journal of clinical endocrinology and metabolism. 2002;87:5662-5667. doi: 10.1210/jc.2002-020635
- 33. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Molecular and cellular endocrinology. 2004;219:9-15. doi: 10.1016/j.mce.2004.03.002
- 34. Després JP. Is visceral obesity the cause of the metabolic syndrome? Annals of medicine. 2006;38:52-63. doi: 10.1080/07853890500383895
- 35. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments. Diabetes. 2002;51:1005-1015. doi: 10.2337/diabetes.51.4.1005

- 36. Kim G, Jo K, Kim KJ, Lee YH, Han E, Yoon HJ, Wang HJ, Kang ES, Yun M. Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes. Cardiovascular diabetology. 2015;14:148. doi: 10.1186/s12933-015-0310-4
- 37. Neeland IJ, Gupta S, Avers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A, McGuire DK, Vega GL, et al. Relation of regional fat distribution to left ventricular structure and function. Circulation Cardiovascular imaging. 2013;6:800-807. doi: 10.1161/circimaging.113.000532
- 38. Evin M, Broadhouse KM, Callaghan FM, McGrath RT, Glastras S, Kozor R, Hocking SL, Lamy J, Redheuil A, Kachenoura N, et al. Impact of obesity and epicardial fat on early left atrial dysfunction assessed by cardiac MRI strain analysis. Cardiovascular diabetology. 2016;15:164. doi: 10.1186/s12933-016-0481-7
- 39. Marinou K, Hodson L, Vasan SK, Fielding BA, Banerjee R, Brismar K, Koutsilieris M, Clark A, Neville MJ, Karpe F. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes care. 2014;37:821-829. doi: 10.2337/dc13-1353
- 40. Peppa M, Koliaki C, Hadjidakis DI, Garoflos E, Papaefstathiou A, Katsilambros N, Raptis SA, Dimitriadis GD. Regional fat distribution and cardiometabolic risk in healthy postmenopausal women. Eur J Intern Med. 2013;24:824-831. doi: 10.1016/j.ejim.2013.07.001
- 41. Goss AM, Gower BA. Insulin sensitivity is associated with thigh adipose tissue distribution in healthy postmenopausal women. Metabolism: clinical and experimental. 2012;61:1817-1823. doi: 10.1016/j.metabol.2012.05.016
- 42. Duran I, Martakis K, Alberg E, Jackels M, Ewert KR, Schoenau E. Association of Trunk/Leg Fat Mass Ratio with Low-Density Lipoproteins-Cholesterol and Triglycerides Concentration in Children and Adolescents: A Cross-Sectional, Retrospective Study. Childhood obesity (Print). 2020;16:428-439. doi: 10.1089/chi.2019.0307
- 43. Samouda H, De Beaufort C, Stranges S, Hirsch M, Van Nieuwenhuyse JP, Dooms G, Gilson G, Keunen O, Leite S, Vaillant M, et al. Cardiometabolic risk: leg fat is protective during childhood. Pediatric diabetes. 2016;17:300-308. doi: 10.1111/pedi.12292
- 44. Cui B, Li W, Wang G, Li P, Zhu L, Zhu S. The predictive value of trunk/leg fat ratio for type 2 diabetes mellitus remission after bariatric surgery: A new observation and insight. Front Endocrinol (Lausanne). 2022;13:1068917. doi: 10.3389/fendo.2022.1068917
- Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Yudkin JS, Heine RJ, Nijpels G, Seidell 45. JC. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes care. 2004;27:372-377. doi: 10.2337/diacare.27.2.372
- Han E, Lee YH, Lee BW, Kang ES, Lee IK, Cha BS. Anatomic fat depots and cardiovascular risk: a 46. focus on the leg fat using nationwide surveys (KNHANES 2008-2011). Cardiovascular diabetology. 2017;16:54. doi: 10.1186/s12933-017-0536-4
- 47. Kishimoto I. Trunk-to-Leg Fat Ratio - An Emerging Early Marker of Childhood Adiposity, and Future Cardiometabolic Risks. Circulation journal : official journal of the Japanese Circulation Society. 2016;80:1707-1709. doi: 10.1253/circj.CJ-16-0635

# **FIGURE LEGENDS**

### Figure 1. Schematic diagram of body region fat and study flowchart

NHANES. National Health and Nutrition Examination Survey: CVD, cardiovascular disease: CHD, coronary heart disease; DXA, Dual-Energy X-ray Absorptiometry; MR, mendelian randomization; SNPs, Single Nucleotide Polymorphisms; HFM, head fat mass; AFM, arm fat mass; TFM, trunk fat mass; LFM, leg fat mass; RFP, regional fat percentage; HFP, head fat percentage; AFP, arm fat percentage; TFP, trunk fat percentage; LFP, leg fat percentage.

### Figure 2. Restricted cubic spline analysis of the linear relationship between regional

### body fat and heart disease

### Figure 3. Subgroup analysis of the association between regional body fat and heart

#### disease

PIR, poverty income ratio; OR, odds ratio.

### Figure 4. Mendelian randomization meta-analysis of the relationship between

### regional body fat and coronary heart disease

CHD, coronary heart disease; OR, odds ratio.

Table1 Baseline characteristics of the population

	Overall	Cardi	ovascular Disease		н	eart Disease			Stroke	
	n = 10159	NO	YES		NO	YES		NO	YES	
Characteristic	N - 110 290 240	n = 9811	n = 347	Ρ	n = 9913	n = 245	Ρ	n = 10029	n = 129	Р
	11 - 113,303,343	N = 116,094,464	N = 3,294,885		N = 116,939,940	N = 2,449,409		N = 118,284,799	N = 1,104,550	
Male	5,171 (52%)	4,991 (52%)	180 (54%)	0.6	5,040 (52%)	131 (55%)	0.4	5,107 (52%)	64 (47%)	0.4
Age	39 (12)	39 (12)	49 (9)	<0.001	39 (12)	49 (8)	<0.001	39 (12)	48 (11)	<0.001
Education				<0.001			<0.001			<0.001
9-11th Grade	1,229 (9.2%)	1,161 (8.9%)	68 (17%)		1,182 (9.0%)	47 (15%)		1,203 (9.0%)	26 (24%)	
College Graduate or above	2,792 (33%)	2,741 (33%)	51 (14%)		2,750 (33%)	42 (15%)		2,780 (33%)	12 (11%)	
High School Grad/GED or	2,214 (22%)	2,123 (21%)	91 (28%)		2,159 (21%)	55 (25%)		2,172 (21%)	42 (31%)	
Equivalent										
Less Than 9th Grade	639 (4.0%)	616 (4.0%)	23 (4.6%)		622 (4.0%)	17 (4.8%)		630 (4.0%)	9 (5.1%)	
Some College or AA	3,282 (33%)	3,168 (33%)	114 (36%)		3,198 (33%)	84 (40%)		3,242 (33%)	40 (29%)	
degreek										
Race				0.021			0.053			0.004
Mexican American	1,521 (11%)	1,486 (11%)	35 (7.6%)		1,501 (11%)	20 (6.0%)		1,506 (11%)	15 (9.5%)	
Non-Hispanic Black	2,095 (11%)	2,000 (11%)	95 (16%)		2,033 (11%)	62 (14%)		2,052 (11%)	43 (23%)	
Non-Hispanic White	3,483 (61%)	3,346 (61%)	137 (59%)		3,378 (61%)	105 (65%)		3,437 (61%)	46 (50%)	

	Overall	Card	iovascular Disease		н	eart Disease	Stroke			
	n = 10158	NO	YES		NO	YES		NO	YES	
Characteristic	N - 110 380 340	n = 9811	n = 347	Ρ	n = 9913	n = 245	Ρ	n = 10029	n = 129	Ρ
_	N - 113,303,343	N = 116,094,464	N = 3,294,885		N = 116,939,940	N = 2,449,409		N = 118,284,799	N = 1,104,550	
Other Hispanic	1,062 (7.5%)	1,025 (7.5%)	37 (7.7%)		1,034 (7.5%)	28 (7.6%)		1,052 (7.5%)	10 (6.6%)	
Other Race	1,997 (9.9%)	1,954 (9.5%)	43 (9.7%)		1,967 (9.5%)	30 (7.3%)		1,982 (9.5%)	15 (5.5%)	
PIR.group				<0.001			<0.001			<0.001
Below poverty(<1.0)	2,102 (16%)	1,994 (16%)	108 (28%)		2,024 (16%)	78 (28%)		2,060 (16%)	42 (38%)	
Above poverty(≥1.0)	7,249 (84%)	7,041 (84%)	208 (72%)		7,104 (84%)	145 (72%)		7,175 (84%)	74 (62%)	
Smoke.group				<0.001			<0.001			<0.001
Current smoker	2,256 (21%)	2,106 (21%)	150 (45%)		2,158 (21%)	98 (42%)		2,189 (21%)	67 (59%)	
Former smoker	1,691 (19%)	1,619 (19%)	72 (23%)		1,632 (19%)	59 (26%)		1,675 (20%)	16 (11%)	
Never smoker	6,204 (59%)	6,079 (60%)	125 (32%)		6,116 (60%)	88 (32%)		6,158 (59%)	46 (30%)	
Height (inches)	67.0 (3.9)	67.0 (3.9)	67.0 (4.1)	0.8	67.0 (3.9)	67.0 (4.2)	0.7	67.0 (3.9)	66.3 (4.3)	0.3
Weight (pounds)	178 (43)	178 (43)	193 (49)	<0.001	178 (43)	196 (50)	<0.001	178 (43)	184 (51)	0.6
BMI.group				<0.001			<0.001			0.3
<24	2,610 (26%)	2,553 (26%)	57 (16%)		2,571 (26%)	39 (15%)		2,589 (26%)	21 (22%)	
24-28	2,686 (27%)	2,612 (27%)	74 (22%)		2,638 (27%)	48 (20%)		2,657 (27%)	29 (22%)	

	Overall	Cardi	ovascular Disease		н	eart Disease			Stroke	
	n - 10159	NO	YES		NO	YES		NO	YES	
Characteristic	N = 119 389 349	n = 9811	n = 347	Ρ	n = 9913	n = 245	Р	n = 10029	n = 129	Ρ
	11 110,000,010	N = 116,094,464	N = 3,294,885		N = 116,939,940	N = 2,449,409		N = 118,284,799	N = 1,104,550	
>28	4,830 (47%)	4,616 (47%)	214 (63%)		4,674 (47%)	156 (65%)		4,751 (47%)	79 (56%)	
Diabetes	1,056 (7.8%)	966 (7.4%)	90 (22%)	<0.001	984 (7.4%)	72 (25%)	<0.001	1,029 (7.7%)	27 (17%)	<0.001
Hypertension	2,639 (25%)	2,413 (24%)	226 (60%)	<0.001	2,474 (24%)	165 (59%)	<0.001	2,556 (24%)	83 (66%)	<0.001
Dyslipidemia	4,296 (42%)	4,042 (41%)	254 (75%)	<0.001	4,113 (42%)	183 (76%)	<0.001	4,204 (42%)	92 (73%)	<0.001
Head Fat Mass (g)	1,166 (162)	1,164 (161)	1,216 (185)	<0.001	1,165 (161)	1,224 (186)	<0.001	1,166 (161)	1,186 (202)	0.7
Arm Fat Mass (g)	3,322 (1,522)	3,307 (1,511)	3,850 (1,785)	<0.001	3,310 (1,513)	3,935 (1,803)	<0.001	3,320 (1,519)	3,628 (1,814)	0.3
Trunk Fat Mass (g)	13,105 (6,076)	13,030 (6,042)	15,757 (6,649)	<0.001	13,040 (6,046)	16,222 (6,688)	<0.001	13,092 (6,066)	14,510 (6,983)	0.10
Leg Fat Mass (g)	9,648 (4,054)	9,636 (4,045)	10,086 (4,374)	0.2	9,636 (4,045)	10,222 (4,434)	0.2	9,649 (4,052)	9,607 (4,360)	0.8
Head Fat Percent (%)	24.07 (0.65)	24.06 (0.64)	24.34 (0.75)	<0.001	24.06 (0.65)	24.38 (0.74)	<0.001	24.07 (0.65)	24.29 (0.74)	0.003
Arm Fat Percent (%)	33 (11)	33 (11)	36 (12)	0.016	33 (11)	36 (11)	0.021	33 (11)	35 (12)	0.12
Trunk Fat Percent (%)	32 (9)	32 (9)	34 (8)	<0.001	32 (9)	35 (8)	<0.001	32 (9)	33 (9)	0.2
Leg Fat Percent (%)	35 (10)	35 (10)	35 (10)	0.5	35 (10)	36 (9)	0.5	35 (10)	35 (10)	0.8

N,weight; PIR, poverty income ratio; BMI, body mass index

Leg Fat Mass

30

Head Fat Mass	Arm Fat Mass	Trunk Fat Mass

Table 2 Correlation coefficients between fat mass in different body regions

Head Fat Mass	1	0.331975	0.426939	0.209801
Arm Fat Mass	0.331975	1	0.923785	0.856195
Trunk Fat Mass	0.426939	0.923785	1	0.796021
Leg Fat Mass	0.209801	0.856195	0.796021	1

Table 3 Weighted logistic regression between fat mass and percentage in various body regions and heart disease

	Model I OR (95%CI)	Р	Model II OR (95%CI)	Р	Model III OR (95%CI)	Р
Regional Fat Mass						
Head Fat Mass (Unit:0.1kg)	1.22 (1.09 , 1.37)	0.001	1.31 (1.11 ,1.55)	0.002	1.31 (1.11 ,1.54)	0.002
Arm Fat Mass (Unit: kg)	1.24 (1.12 , 1.38)	<0.001	1.25 (1.10 ,1.41)	0.001	1.18 (1.00 ,1.38)	0.047
Trunk Fat Mass (Unit:2.5kg)	1.19 (1.12 , 1.28)	<0.001	1.17 (1.07 ,1.27)	<0.00 1	1.14 (1.02 ,1.28)	0.027
Leg Fat Mass (Unit: kg)	1.03 (0.99 , 1.08)	0.12	1.05 (1.00 , 1.11)	0.069	1.01 (0.94 ,1.08)	0.874
Regional Fat Percentage						
Head Fat Percent (%)	1.68 (1.37 , 2.05)	<0.001	1.58 (1.23 , 2.03)	0.001	1.37 (1.06 ,1.77)	0.018
Arm Fat Percent (%)	1.02 (1.00 , 1.04)	0.016	1.05 (1.01 , 1.08)	0.009	1.03 (0.99 ,1.07)	0.154
Trunk Fat Percent (%)	1.05 (1.02 , 1.07)	<0.001	1.05 (1.01 , 1.09)	0.008	1.04 (0.99 ,1.09)	0.138
Leg Fat Percent (%)	1.01 (0.99 , 1.02)	0.428	1.02 (0.99 , 1.06)	0.218	1.00 (0.96 ,1.04)	0.801

Model I adjusted for: none

Model II adjusted for: age, gender, race

Model III adjusted for: age, gender, race, education, poverty income ratio, body mass index, smoking

31

#### Figure 1.







### Figure 2.



Figure 3.

Variable	Count	Head Fat Mass (Unit:0.1kg)	OR (95% CI)	P for interaction	Arm Fat	Mass (Unit:kg)	OR (95% CI)	P for interaction	Trunk Fat Mass (Unit:2.5kg)	OR (95% CI)	P for interaction	Leg Fat Mass (Unit:kg)	OR (95% CI)	P for interaction
Overall	10158		1.22 (1.09 to 1.37)			-	1.24 (1.12 to 1.38)		. •	1.19 (1.12 to 1.28)		•	1.03 (0.99 to 1.08)	
Gender		:		0.773		1		0.871	1		0.915	1		0.47
Female	4987	· · · · · · · · · · · · · · · · · · ·	1.27 (1 to 1.6)				1.27 (1.08 to 1.51)			1.2 (1.06 to 1.35)			1.03 (0.96 to 1.11)	
Male	5171	·	1.32 (1.11 to 1.56)				1.3 (1.15 to 1.46)		-	1.21 (1.13 to 1.29)		+	1.07 (1.02 to 1.12)	
Age				0.736				0.38			0.131	1		0.072
20-44	6491	·	1.26 (1.1 to 1.45)				1.29 (1.14 to 1.47)			1.25 (1.16 to 1.34)		-	1.09 (1.03 to 1.15)	
45~59	3667	·	1.22 (1.06 to 1.41)			<u> </u>	1.18 (1.01 to 1.38)		·	1.13 (1.02 to 1.26)		+	1.01 (0.95 to 1.07)	
PIR				<0.001				0.019	1		0.004			0.014
>1	7220	·	1.39 (1.21 to 1.6)				1.32 (1.19 to 1.47)		. +	1.26 (1.18 to 1.34)		+	1.06 (1.02 to 1.1)	
≤1	2131		0.81 (0.64 to 1.01)		-	+	1.02 (0.83 to 1.25)			1.01 (0.89 to 1.16)			0.95 (0.88 to 1.03)	
Smoke		1		0.124				0.089	1		0.135			0.52
No	6209		1.38 (1.17 to 1.62)				1.37 (1.19 to 1.57)			1.26 (1.16 to 1.38)			1.06 (1 to 1.12)	
Yes	3949	֥	1.13 (0.95 to 1.34)				1.19 (1.05 to 1.34)			1.15 (1.05 to 1.26)		-	1.03 (0.98 to 1.08)	
Obesity		1		0.175				0.418	1		0.08	1		0.681
No	5996	<u> </u>	1 (0.79 to 1.27)			· · · · · ·	1.29 (0.92 to 1.82)			1.36 (1.08 to 1.73)			0.96 (0.88 to 1.06)	
Yes	4130		1.22 (1.06 to 1.4)			÷	1.13 (0.98 to 1.31)			1.13 (1.03 to 1.24)		+	0.98 (0.93 to 1.04)	
Hypertensio	n			0.098		1		0.028			0.015			0.237
No	7519	; <del></del>	1.24 (1.07 to 1.44)			·	1.31 (1.13 to 1.52)		÷	1.24 (1.14 to 1.36)		+	1.05 (0.99 to 1.1)	
Yes	2639	<b>_</b>	1.05 (0.9 to 1.23)		-	+	1.05 (0.91 to 1.21)			1.04 (0.93 to 1.16)		+	1 (0.94 to 1.06)	
Diabetes		1		0.287				0.689	1		0.394			0.248
No	9102		1.2 (1.03 to 1.38)				1.18 (1.05 to 1.33)			1.16 (1.07 to 1.26)		+	1.01 (0.96 to 1.06)	
Yes	1056		1.07 (0.92 to 1.24)			+•	1.13 (0.93 to 1.37)			1.1 (0.99 to 1.22)			1.06 (0.99 to 1.13)	
Dyslipidemia	1			0.269				0.043	1		0.023			0.02
No	5862	·	1.25 (1.02 to 1.53)			·	1.35 (1.18 to 1.56)		·	1.26 (1.14 to 1.4)		+	1.1 (1.04 to 1.16)	
Yes	4296	֥	1.1 (0.96 to 1.25)			<b>↓</b> • •	1.14 (0.99 to 1.3)		<b>→</b>	1.1 (1.01 to 1.21)		+	1.01 (0.95 to 1.06)	
		0.5 1 1.5			0.5	1 15			0.5 1 1.5			05 1 15		

Variable	Count	Head Fat Percent	OR (95% CI)	P for interaction	Arm Fat Percent	OR (95% CI)	P for interaction	Trunk Fat Percent	OR (95% CI)	P for interaction	Leg Fat Percent	OR (95% CI)	P for interaction
Overall	10158	-	1.68 (1.37 to 2.05)			1.02 (1 to 1.04)			1.05 (1.02 to 1.07)			1.01 (0.99 to 1.02)	
Gender				0.337			0.276	1		0.609	1		0.245
Female	4987		1.81 (1.42 to 2.3)			1.04 (1 to 1.09)			1.06 (1.01 to 1.13)		+	1.01 (0.96 to 1.06)	
Male	5171		1.53 (1.15 to 2.04)		·	1.08 (1.04 to 1.11)		1 +	1.08 (1.05 to 1.12)		÷+-	1.04 (1.01 to 1.08)	
Age				0.364			0.052			0.052			0.007
20-44	6491	·	1.81 (1.47 to 2.24)		+	1.03 (1.01 to 1.05)		+	1.06 (1.03 to 1.09)		-	1.03 (1.01 to 1.06)	
45~59	3667		1.52 (1.12 to 2.06)		+	1.01 (0.99 to 1.03)		+	1.02 (0.99 to 1.06)		+	0.99 (0.97 to 1.01)	
PIR				0.014			0.316	1		0.018	1		0.819
>1	7220		1.82 (1.42 to 2.33)		+	1.03 (1 to 1.05)		+	1.06 (1.03 to 1.09)		+	1.01 (0.99 to 1.03)	
≤1	2131	+•	1.17 (0.87 to 1.57)		+	1.01 (0.98 to 1.04)		+	1.01 (0.97 to 1.05)		+	1 (0.98 to 1.03)	
Smoke				0.361	1		0.551			0.196	1		0.789
No	6209		1.81 (1.34 to 2.45)		<b>↓</b>	1.03 (1 to 1.06)		-	1.07 (1.03 to 1.11)		+	1.01 (0.98 to 1.04)	
Yes	3949		1.56 (1.23 to 1.97)		+	1.02 (1 to 1.04)		+	1.04 (1.01 to 1.07)		+	1.01 (1 to 1.03)	
Obesity				0.863			0.616			0.217	1		0.395
No	5996		- 1.56 (0.88 to 2.75)		+	1.01 (0.99 to 1.04)			1.05 (1.01 to 1.09)		+	1 (0.98 to 1.03)	
Yes	4130		1.47 (1.14 to 1.88)		+	1.01 (0.98 to 1.03)		+-	1.02 (0.98 to 1.05)		+	0.99 (0.96 to 1.02)	
Hypertensio	n			0.062			0.324			0.089			0.556
No	7519	·	1.82 (1.28 to 2.59)		i+-	1.02 (1 to 1.05)		-	1.05 (1.02 to 1.09)		+	1.01 (0.99 to 1.03)	
Yes	2639		1.23 (0.95 to 1.6)		+	1.01 (0.99 to 1.03)		+	1.01 (0.98 to 1.05)		+	1 (0.98 to 1.02)	
Diabetes				0.273	1		0.816	1		0.732	1		0.62
No	9102		1.58 (1.22 to 2.04)		+	1.01 (1 to 1.03)		-	1.04 (1.01 to 1.07)		÷	1 (0.99 to 1.02)	
Yes	1056		1.26 (0.92 to 1.74)		+	1.02 (0.98 to 1.06)			1.03 (0.98 to 1.08)			1.02 (0.97 to 1.06)	
Dyslipidemia	1			0.52			0.08	1		0.032			0.094
No	5862		1.64 (1 to 2.68)		+	1.04 (1.01 to 1.07)		-	1.07 (1.03 to 1.11)		+	1.04 (1.01 to 1.07)	
Yes	4296		1.38 (1.08 to 1.75)		÷	1.01 (0.99 to 1.03)		÷	1.02 (0.99 to 1.06)		÷	1 (0.98 to 1.03)	
		0.5 1 2			0.8 1	1.5		0.8 1	1.5		0.8 1	1.5	

Figure 4.

study arm fat mass to CHD nsn	р	OR (95% CI)	pval	study trunk fat mass to CHD	nsnp		OR (95% CI)	pval	study leg fat mass to CHD	nsnp		OR (9	5% CI)	p
ukb-a-283   finn-b-l9 CHD 271	· · · · · · · · · · · · · · · · · · ·	1 235 (1 108 to 1 3	77) 0.000	ukb-a-291   finn-b-l9 CHD	285	<u> </u>	1 101 (0 991 to 1 22	4) 0.073	ukb-a-275   ukb-b-1668	284		1 014	(1 011 to 1 01	18) 0
ukb-a-283 Lieu-a-6 142		1 461 (1 229 to 1 7	35) 0.000	ukb-a-201 Lieu-a-6	142		1 344 (1 121 to 1 61	2) 0.001	ukb-a-275 Lieu-a-6	146	· · · ·	1 446	(1 168 to 1 79	92) 0
ukb-a-283 Lieu-a-9 86		1 465 (1 260 to 1 7	03) 0.000	ukb-a-291 Lieu-a-9	80		- 1 280 (1 084 to 1 51)	3) 0.004	ukb-a-275 Lieu-a-9	87		1.455	(1 220 to 1 73	36) 0
kb-a-283 Lukb-b-1668 274		1.010 (1.007 to 1.0	13) 0.000	ukb=a=291   ukb=b=1668	287		1.006 (1.004 to 1.01	9) 0.000	ukb-a-275 Lukb-b-1668	284		1.400	(1.011 to 1.01	18) (
kb-a-283 Lukb-b-7436 271		1.005 (1.003 to 1.0	07) 0.000	ukb-a-291 Lukb-b-7436	270	1	1.000 (1.003 to 1.003	5) 0.000	ukb-a-275 Lukb-b-7436	277	1	1.008	(1.005 to 1.01	10) (
kb-a-283 Lukb-d-19 CHD 277	1	1.014 (1.010 to 1.0	17) 0.000	ukb-a-201 Lukb-d-I0 CHD	200	1	1.004 (1.002 to 1.003	3) 0.000	ukb-a-275 Lukb-d-19 CHC	288	1	1.000	(1.013 to 1.07	22) 1
kb-a-203   0kb-d-13_0110 277		1.014 (1.070 to 1.0	17) 0.000	ukb b 20044 l fan b 10 CUD	250	1	1.000 (1.000 to 1.01	4) 0.000	ukb-a-270   fipp-b-10_CHC	200	1	1 202	(1.145 to 1.49	22) 1
kb-a-207   IIIII-b-I9_CHD 273		1.193 (1.072 to 1.3)	12) 0.001	ukb-b-20044   IIIII-b-I9_CHD	007		1.104 (1.004 to 1.214	4) 0.042	ukb-a-279   IIIII-b-I3_CITC	151	1	1.505	(1.145 10 1.40	102)
10-a-207   leu-a-6 134		1.615 (1.304 to 1.9	13) 0.000	ukb-b-20044   leu-a-6	221	1	1.348 (1.144 to 1.58	6) 0.000	ukb-a-279   leu-a-6	151	4	1.404	(1.101 10 1.01	10)
IKD-a-267   Ieu-a-9 82		1.510 (1.303 to 1.7	50) 0.000	ukb-b-20044   leu-a-9	120	-	- 1.270 (1.097 to 1.47	1) 0.001	ukb-a-279   leu-a-9	0/		1.495	(1.237 to 1.60	100)
KD-a-287   UKD-D-1668 275	1	1.011 (1.008 to 1.0	14) 0.000	ukb-b-20044   ukb-b-1668	414	1	1.007 (1.004 to 1.01)	0) 0.000	ukb-a-279   ukb-b-1668	287	1	1.014	(1.010 to 1.01	18)
IKD-a-287   UKD-D-7436 270		1.006 (1.004 to 1.00	0.000 (80	ukb-b-20044   ukb-b-7436	404		1.004 (1.002 to 1.00	6) 0.000	ukb-a-279   ukb-b-7436	2/9		1.007	(1.005 to 1.01	10)
ikb-a-287   ukb-d-19_CHD 278		1.014 (1.011 to 1.0	17) 0.000	ukb-b-20044   ukb-d-l9_CHD	0 422	1	1.009 (1.006 to 1.01)	2) 0.000	ukb-a-279   ukb-d-19_CHL	291	1	1.018	(1.014 to 1.02	22)
kb-b-6704   finn-b-19_CHD 423		1.187 (1.074 to 1.3)	12) 0.001	Fixed effect model		1	1.006 (1.005 to 1.00)	7) 0.000	ukb-b-7212   finn-b-I9_CH	D 422		1.301	(1.142 to 1.48	82)
ikb-b-6704   ieu-a-6 229		1.577 (1.357 to 1.83	32) 0.000	Random effect model			1.084 (1.022 to 1.14	9) 0.007	ukb-b-7212   ieu-a-6	231		• 1.575	(1.296 to 1.91	15)
ikb-b-6704   ieu-a-9 115		1.450 (1.257 to 1.6)	72) 0.000		0.98	81	1.65		ukb-b-7212   ieu-a-9	108		1.458	(1.199 to 1.77	73)
kb-b-6704   ukb-b-1668 422		1.010 (1.008 to 1.0)	13) 0.000						ukb-b-7212   ukb-b-7436	405		1.007	(1.005 to 1.00	09)
kb-b-6704   ukb-b-7436 415		1.006 (1.004 to 1.00	07) 0.000						ukb-b-7212   ukb-b-7436	405		1.007	(1.005 to 1.00	09)
kb-b-6704   ukb-d-I9_CHD 427		1.013 (1.009 to 1.01	16) 0.000						ukb-b-7212   ukb-d-I9_CH	D 424	+	1.015	(1.011 to 1.01	19)
ikb-b-8338   finn-b-I9_CHD 415		1.211 (1.095 to 1.33	38) 0.000						ukb-b-18096   finn-b-l9_C	HD 425		1.302	(1.150 to 1.47	75)
1kb-b-8338   ieu-a-6 221		1.614 (1.386 to 1.8)	79) 0.000						ukb-b-18096   ieu-a-6	237		• 1.567	(1.290 to 1.90	04)
kb-b-8338   ieu-a-9 115		1.452 (1.257 to 1.6)	76) 0.000						ukb-b-18096   ieu-a-9	108		1.518	(1.267 to 1.81	19)
kb-b-8338   ukb-b-1668 413	-	1.011 (1.008 to 1.01	14) 0.000						ukb-b-18096   ukb-b-1668	417		1.014	(1.010 to 1.01	17)
kb-b-8338   ukb-b-7436 408		1.006 (1.004 to 1.00	000.0 (80						ukb-b-18096   ukb-b-7436	410	÷	1.007	(1.005 to 1.01	10)
kb-b-8338   ukb-d-I9 CHD 421	- <b>1</b>	1.013 (1.010 to 1.0)	16) 0.000						ukb-b-18096   ukb-d-l9_C	HD 427		1.015	(1.011 to 1.01	19)
Fixed effect model		1.008 (1.008 to 1.00	000.0 (60						Fixed effect model			1.010	(1.009 to 1.01	11)
		1 174 (1 092 to 1 2	61) 0.000						Random effect model			1,161	(1.083 to 1.24	45)
andom effect model	1 1	.96	01) 0.000								1	1.96		
andom effect model	1 1	.96		(E)					(F)		1	1.96	¥ 01	
andom effect model	1 1 1	.96 OR (95% CI)	pval	(E) study trunk fat precent to Ci	HD nsnr	9	OR (95% CI)	pval	(F) study leg fat precent to CHD	nsnp	1	1.96 OR (959	% CI)	,
tudy arm fat precent to CHD nsr hts-282   finn-b-19_CHD 237	1 1 1 1	96 OR (95% Cl) 1.340 (1.131 to 1.5	pval 87) 0.001	(E) study trunk fat precent to Cl ukb-a-290   finn-b-I9_CHD	HD nsnp 235	o ∔∙	<b>OR (95% CI)</b> 1.084 (0.950 to 1.2	<b>pval</b> 236) 0.231	(F) study leg fat precent to CHD ukb-a-274   ukb-d-I9_CHD	nsnp 251	•	1.96 OR (959 1.023 (1	% <b>CI)</b> I.017 to 1.029)	F () (
andom effect model tudy arm fat precent to CHD nsr kb-a-282   finn-b-19_CHD 233 kb-a-282   ieu-a-6 125		OR (95% CI) 1.340 (1.131 to 1.5 - 1.898 (1.475 to 2.4	pval 87) 0.001 44) 0.000	(E) study trunk fat precent to Ci ukb-a-290   finn-b-I9_CHD ukb-a-290   ieu-a-6	HD nsnp 235 123	, 	OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9	<b>pval</b> 236) 0.231 926) 0.000	(F) study leg fat precent to CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ieu-a-6	<b>nsnp</b> 251 129		1.96 OR (95 1.023 (1 — 1.738 (1	% CI) 1.017 to 1.029 1.327 to 2.277)	F (9) (0 7) (0
) tudy arm fat precent to CHD nsr kb-a-282   finn-b-19_CHD 237 kb-a-282   ueu-a-6 122 kb-a-282   ueu-a-9 75		OR (95% Cl) 1.340 (1.131 to 1.5 - 1.898 (1.475 to 2.4 1.663 (1.322 to 2.0	pval 87) 0.001 44) 0.000 93) 0.000	(E) study trunk fat precent to Cl ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-a-290   ieu-a-9	HD nsnp 235 123 74	, 	OR (95% CI) 1.084 (0.950 to 1.2 - 1.553 (1.253 to 1.9 - 1.219 (0.992 to 1.4	pval 236) 0.231 926) 0.000 497) 0.060	(F) study leg fat precent to CHD ukb=a-274   ukb-d=9_CHD ukb=a-274   ieu-a-6 ukb=a-274   ieu-a-9	nsnp 251 129 77		1.96 OR (95 1.023 (1 	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232	P) 0 7) 0 2) 0
) tudy arm fat precent to CHD ner hardson arm fat precent to CHD		OR (95% CI) 1.340 (1.131 to 1.5 1.683 (1.475 to 2.4 1.683 (1.322 to 2.0 1.014 (1.009 to 1.0	pval 87) 0.001 44) 0.000 93) 0.000 19) 0.000	(E) study trunk fat precent to C1 ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-a-290   ieu-a-9 ukb-b-1407   finn-b-19_CH	HD nsnp 235 123 74 HD 380		OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 - 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2	pval 236) 0.231 326) 0.000 497) 0.060 238) 0.139	(F) study leg fat precent to CHD ukb-a-274   ukb-d-H2_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-9 ukb-a-274   ukb-b-1668	nsnp 251 129 77 249		1.96 OR (95 1.023 (1 	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027	P ) 0 ) 0 ) 0 ) 0 ) 0 ) 0
tudy arm fat precent to CHD   nsr     kb-a-282   finn-b-lg_CHD   237     kb-a-282   eura-a   122     kb-a-282   eura-a   75     kb-a-282   eura-b-b-1668   232     kb-a-282   eura-b-b-1668   233		OR (95% Cl) 1.340 (1.131 to 1.5 - 1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.041 (1.009 to 1.0 1.047 (1.009 to 1.0	pval 87) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.000	(E) study trunk fat precent to C1 ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-a-290   ieu-a-6 ukb-b-16407   finu-b-19_CH ukb-b-16407   ieu-a-6	HD nsnp 235 123 74 HD 380 200	2 	OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.2 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8	pval 236) 0.231 326) 0.000 497) 0.060 238) 0.139 318) 0.000	(F) study leg fat precent to CHD ukb-a-274   ukb-d-l9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-9 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-7436	nsnp 251 129 77 249 243		1.96 OR (95 1.023 (1 	% CI) 1.017 to 1.029) 1.327 to 2.277 1.326 to 2.232) 1.016 to 1.027) 1.008 to 1.014)	P () () () () () () () () () ()
) tudy arm fat precent to CHD ns. http://www.ns. http://wwww.ns. http://ww		OR (95% Cl) 1.340 (1.131 to 1.5 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.004 to 1.0 1.285 (1.094 to 1.5	pval 187) 0.001 144) 0.000 193) 0.000 10) 0.000 10) 0.002	(E) study trunk fat precent to Cl ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   finn-b-19_CH ukb-b-16407   finn-b-19_CH ukb-b-16407   ieu-a-6	HD nsnp 235 123 74 HD 380 200 117		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.960 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.424 (1.195 to 1.6	pval 236) 0.231 226) 0.000 497) 0.060 238) 0.139 238) 0.139 238) 0.000 590) 0.000	(F) study leg fat precent to CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ieu-a-6 ukb=a-274   ieu-a-9 ukb=a-274   ukb=b-1686 ukb=a-274   ukb=b-7436 ukb=a-274   ukb=0_CHD	nsnp 251 129 77 249 243 251		1.96 OR (95 1.023 (1 	% CI) 1.017 to 1.029) 1.327 to 2.277) 1.326 to 2.232] 1.016 to 1.027) 1.008 to 1.014] 1.017 to 1.029)	P ) 0 ) 0 ) 0 ) 0 ) 0 ) 0 ) 0 ) 0
Vandom effect model     tudy arm fat precent to CHD   psr     kb-a-282   fiun-b-l9_CHD   237     kb-a-282   iuu-a-6   122     kb-a-282   iuu-a-6   126     kb-a-282   iuu-a-6   233     kb-a-282   iuu-b-7436   233     kb-a-286   fiun-b-l9_CHD   253     kb-a-286   fiun-b-19_CHD   135		OR (95% CI) 1.340 (1.131 to 1.5 - 1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.004 to 1.0 1.285 (1.094 to 1.5 1.822 (1.431 to 2.3	pval 877 0.001 449 0.000 939 0.000 199 0.000 100 0.002 200 0.000	(E) study trunk fat precent to C1 ukb-a-290   ieu-a-9 ukb-a-290   ieu-a-6 ukb-a-290   ieu-a-6 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-9	HD nsnp 235 123 74 HD 380 200 117 383		OR (95% CI) 1.084 (0.950 to 1.2 → 1.553 (1.253 to 1.3 - 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 → 1.519 (1.269 to 1.6 1.029 (1.055 to 1.6 1.009 (1.055 to 1.6)	pval 236) 0.231 326) 0.000 497) 0.060 238) 0.139 318) 0.000 318) 0.000 312) 0.000	(F) study leg fat precent to CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ieu-a-6 ukb-a-274   ukb-d-1668 ukb-a-274   ukb-d-1668 ukb-a-274   ukb-d-19_CHD ukb-a-276   finn-b-19_CHD	nsnp 251 129 77 249 243 251 248		0R (95 1.023 (1 - 1.738 (1 - 1.720 (1 1.022 (1 1.012 (1 1.023 (1 1.023 (1 1.023 (1 1.077 (1	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.049 1.017 to 1.029 1.139 to 1.665	<b>p</b> (7) 0 (7)
Aundom effect model     Judy arm fat precent to CHD   nsr     Web-a-282   finn-b-lg_CHD   237     Meb-a-282   ueu-a-6   122     Kb-a-282   ueu-a-6   125     Kb-a-282   ueu-a-6   232     Kb-a-282   ueu-a-6   233     Kb-a-282   ueu-b-1668   233     Kb-a-286   finn-b-12, CHD   255     Kb-a-286   ieu-a-6   135     Kb-a-286   ieu-a-8   80		OR (95% Cl) 1.340 (1.131 to 1.5 1.896 (1.475 to 2.4 1.683 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.004 to 1.0 1.025 (1.094 to 1.5 1.822 (1.431 to 2.3 1.536 (1.229 to 1.9	pval 87) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.002 20) 0.000 20) 0.000	(E) study trunk fat precent to C1 ukb-a-290 [sin-b-19_CHD ukb-a-290 [siu-a-6 ukb-b-16407 [siu-a-9 ukb-b-16407 [siu-a-6 ukb-b-16407 [siu-a-6 ukb-b-16407 [siu-b-6168 ukb-b-16407 [siu-b-7436	HD nsnp 235 123 74 HD 380 200 117 383 371		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.519 (0.992 to 1.4 1.966 (0.970 to 1.2 1.519 (1.269 to 1.8 1.421 (1.195 to 1.6 1.009 (1.005 to 1.0 1.005 (1.003 to 1.0	pval 236) 0.231 326) 0.000 497) 0.060 238) 0.139 318) 0.000 5900 0.000 5901 0.000 507) 0.000	(F) study leg fat precent to CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-274   ukb=d-19_CHD ukb=a-278   finn=b-19_CHD ukb=a-278   finn=b-19_CHD	nsnp 251 129 77 249 243 251 248 126		0R (95 1.023 (1 1.738 (1 1.738 (1 1.720 (1 1.022 (1 1.011 (1 1.023 (1 1.023 (1 1.017 (1 1.027 (1 1.079 (1	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.014 1.017 to 1.029 1.139 to 1.665 1.260 to 2.235	p ) 0 ) 0 ) 0 ) 0 ) 0 ) 0 ) 0 ) 0
Yudy arm fat precent to CHD   ns     kb-a-282   finn-b-l9_CHD   237     kb-a-282   ieu-a-6   122     kb-a-282   ieu-a-6   125     kb-a-282   ieu-a-6   233     kb-a-282   ieu-a-9   75     kb-a-282   ieu-b-7436   233     kb-a-286   ieu-a-6   135     kb-a-286   ieu-a-6   135     kb-a-286   ieu-a-6   806     kb-a-286   ieu-b-7686   255		OR (95% Cl) 1.340 (1.131 to 1.5 - 1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.041 (1.009 to 1.0 1.047 (1.009 to 1.0 1.285 (1.094 to 1.5 1.822 (1.431 to 2.3 1.536 (1.229 to 1.9 1.015 (1.100 to 1.0	pval 87) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.002 20) 0.000 10) 0.002 20) 0.000 19) 0.000	(E) study trunk fat precent to C1 ukb-a-290 [ieu-a-6 ukb-a-290 [ieu-a-6 ukb-b-16407 [inu-b-19_C+ ukb-b-16407 [ieu-a-6 ukb-b-16407 [ieu-a-6 ukb-b-16407 [ikb-b-1668 ukb-b-16407 [ikb-b-1658	HD nsnp 235 123 74 HD 380 117 383 371 HD 389		OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.619 (1.269 to 1.8 1.009 (1.005 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0)	pval 236) 0.231 926) 0.000 497) 0.060 238) 0.139 818) 0.000 590) 0.000 590) 0.000 590) 0.000 515) 0.000	(F) study leg fat precent to CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ieu-a-6 ukb-a-274   ukb-d-1668 ukb-a-274   ukb-d-1668 ukb-a-274   ukb-d-9_CHD ukb-a-278   ieu-a-6 ukb-a-278   ieu-a-9	nsnp 251 129 77 249 243 251 248 126 68		1.96 OR (95' 1.023 (1 - 1.738 (1 - 1.720 (1 1.022 (1 1.011 (1 1.023 (1 1.377 (1 - 1.679 (1 - 1.679 (1)	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.027 1.139 to 1.665 1.260 to 2.235 1.489 to 2.552	p ) 0 ) 0 ) 0 ) 0 ) 0 ) 0 ) 0 ) 0
tudy arm fat precent to CHD   nsr     btady arm fat precent to CHD   nsr     bta-arease   istage arm fat precent to CHD   nsr		OR (95% CI) 1.340 (1.131 to 1.5 - 1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.004 to 1.0 1.285 (1.094 to 1.5 1.822 (1.431 to 2.3 1.586 (1.291 to 1.9 1.015 (1.010 to 1.0 1.006 (1.005 to 1.0)	pval 87) 0.001 44) 0.000 193 0.000 190 0.000 100 0.002 200 0.000 109 0.000 109 0.000 109 0.000 109 0.000	(E) study trunk fat precent to CI ukb-a-290 [inu-b-19_CHD ukb-a-290 [inu-a-6 ukb-b-16407 [inu-a-9 ukb-b-16407 [inu-a-9 ukb-b-16407 [inu-a-9 ukb-b-16407 [inu-b-7436 ukb-b-16407 [ukb-d-1688 ukb-b-16407 [ukb-d-18]_CF Fixed effect model	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.510 (0.992 to 1.4 1.966 (0.970 to 1.2 1.510 (1.269 to 1.6 1.421 (1.195 to 1.6 1.006 (1.003 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0 1.007 (1.005 to 1.0)	pval 236) 0.231 226) 0.000 497) 0.060 238) 0.139 318) 0.000 390) 0.000 307) 0.000 307) 0.000 305) 0.000 308) 0.000	(F) study leg fat precent to CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-7436 ukb-a-276   ieu-a-9 ukb-a-276   ieu-a-6 ukb-a-276   ieu-a-9 ukb-a-276   ukb-a-1668	nsnp 251 129 77 249 243 251 251 248 126 68 250		0R (95 1.023 (1 1.738 (1 1.738 (1 1.720 (1 1.021 (1 1.023 (1 1.023 (1 1.023 (1 1.027 (1 1.377 (1 1.950 (1	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.014 1.017 to 1.029 1.139 to 1.665 1.260 to 2.2352 1.489 to 2.552 1.016 to 1.027	P (7) 0 (7) 0
Nudy arm fat precent to CHD   nsr     hub;a-282; linn-b-19,CHD   233     kb:a-282; line-a-9   75     kb:a-282; line-b-1668   233     kb:a-282; link-b-1686   236     kb:a-282; link-b-1686   236     kb:a-286; line-a-6   182     kb:a-286; line-a-8   80     kb:a-286; link-b-1668   256     kb:a-286; link-b-1688   256     kb:a-286; link-b-19,CHD   256     kb:a-286; link-b-19,CHD   256     kb:a-286; link-b-19,CHD   257 </td <td></td> <td>96 0R (95% CI) 1.340 (1.131 to 1.5 -1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.071 (1.044 to 1.5 1.822 (1.431 to 2.5 1.822 (1.431 to 2.5 1.536 (1.222 to 1.9 1.015 (1.010 to 1.0 1.005 (1.005 to 1.0) 1.009 (1.014 to 1.0)</td> <td>pval 87) 0.001 44) 0.000 93) 0.000 10) 0.002 10) 0.002 20) 0.000 10) 0.000 10) 0.000 10) 0.000 20) 0.000 10) 0.000 23) 0.000</td> <td>(E) study trunk fat precent to C1 ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   inn-b-19_CH ukb-b-16407   inu-b-9_0 ukb-b-16407   iukb-b-688 ukb-b-16407   ukb-b-7438 ukb-b-16407   ukb-d-19_CF Fixed effect model Random effect model</td> <td>HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389</td> <td></td> <td>OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.3 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.424 (1.195 to 1.6 1.009 (1.005 to 1.0 1.001 (1.008 to 1.0 1.017 (1.005 to 1.0 1.077 (1.005 to 1.0 1.170 (1.044 to 1.3)</td> <td>pval 236) 0.231 326) 0.000 497) 0.060 238) 0.139 318) 0.000 590) 0.000 507) 0.000 507) 0.000 507) 0.000 505) 0.000 505) 0.000 515) 0.000</td> <td>(F) study leg fat precent to CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=d=14 ukb=a-274   ukb=b=1668 ukb=a-274   ukb=b=7436 ukb=a-278   ukb=d=9_CHD ukb=a-278   iou=a=6 ukb=a-278   iou=a=9 ukb=a-278   ukb=b=1668 ukb=a-278   ukb=b=1686</td> <td>nsnp 251 129 77 249 243 251 248 126 68 250 243</td> <td></td> <td>1.96 0R (95 1.023 (1 - 1.728 (1 1.022 (1 1.022 (1 1.022 (1 1.023 (1 - 1.679 (1 - 1.859 (1 1.022 (1 1.022 (1 1.022 (1 1.022 (1) 1.022 (1) 1.</td> <td>% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.014 1.017 to 1.029 1.139 to 1.665 1.260 to 2.235 1.469 to 2.552 1.016 to 1.027 1.008 to 1.015 1.008 to 1.015</td> <td>F (7) 0 (7) 0 (7) 0 (7) 0 (7) 0 (5) 0 (5) 0 (7) 0</td>		96 0R (95% CI) 1.340 (1.131 to 1.5 -1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.071 (1.044 to 1.5 1.822 (1.431 to 2.5 1.822 (1.431 to 2.5 1.536 (1.222 to 1.9 1.015 (1.010 to 1.0 1.005 (1.005 to 1.0) 1.009 (1.014 to 1.0)	pval 87) 0.001 44) 0.000 93) 0.000 10) 0.002 10) 0.002 20) 0.000 10) 0.000 10) 0.000 10) 0.000 20) 0.000 10) 0.000 23) 0.000	(E) study trunk fat precent to C1 ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   inn-b-19_CH ukb-b-16407   inu-b-9_0 ukb-b-16407   iukb-b-688 ukb-b-16407   ukb-b-7438 ukb-b-16407   ukb-d-19_CF Fixed effect model Random effect model	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.3 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.424 (1.195 to 1.6 1.009 (1.005 to 1.0 1.001 (1.008 to 1.0 1.017 (1.005 to 1.0 1.077 (1.005 to 1.0 1.170 (1.044 to 1.3)	pval 236) 0.231 326) 0.000 497) 0.060 238) 0.139 318) 0.000 590) 0.000 507) 0.000 507) 0.000 507) 0.000 505) 0.000 505) 0.000 515) 0.000	(F) study leg fat precent to CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=d=14 ukb=a-274   ukb=b=1668 ukb=a-274   ukb=b=7436 ukb=a-278   ukb=d=9_CHD ukb=a-278   iou=a=6 ukb=a-278   iou=a=9 ukb=a-278   ukb=b=1668 ukb=a-278   ukb=b=1686	nsnp 251 129 77 249 243 251 248 126 68 250 243		1.96 0R (95 1.023 (1 - 1.728 (1 1.022 (1 1.022 (1 1.022 (1 1.023 (1 - 1.679 (1 - 1.859 (1 1.022 (1 1.022 (1 1.022 (1 1.022 (1) 1.022 (1) 1.	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.014 1.017 to 1.029 1.139 to 1.665 1.260 to 2.235 1.469 to 2.552 1.016 to 1.027 1.008 to 1.015 1.008 to 1.015	F (7) 0 (7) 0 (7) 0 (7) 0 (7) 0 (5) 0 (5) 0 (7) 0
tudy arm fat precent to CHD nsr kb-a-282   tinn-b-lg_CHD 237 kb-a-282   tinu-a-6 122 kb-a-282   tinu-a-6 122 kb-a-282   tinu-a-6 125 kb-a-282   tinu-b-1668 235 kb-a-286   tinu-b-1668 235 kb-a-286   tinu-a-6 135 kb-a-286   tinu-a-6 135 kb-a-286   tinu-b-1668 255 kb-a-286   tinu-b-1668 255 kb-a-286   tinu-b-1668 255 kb-a-286   tinb-b-1628 255 kb-a-286   tinb-b-16285   tinn-b-120-CHD 367		OR (95% CI) 1.340 (11.31 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.321 to 2.0 1.014 (1.009 to 1.0 1.027 (1.094 to 1.5 1.536 (1.291 to 1.2 1.536 (1.291 to 1.2 1.015 (1.101 to 1.0 1.015 (1.101 to 1.0) 1.015 (	pval 877 0.001 449 0.000 199 0.000 100 0.000 100 0.000 200 0.000 199 0.000 199 0.000 199 0.000 100 0.0000 100 0.0000 1	(E) study trunk fat precent to C1 ukb-a-290 [sin-b-19_CHD ukb-a-290 [siu-a-6 ukb-b-16407 [sin-b-9_CHD ukb-b-16407 [siu-a-9 ukb-b-16407 [siu-a-9 ukb-b-16407 [siu-a-6 ukb-b-16407 [ukb-b-1688 ukb-b-16407 [ukb-d-7436 ukb-b-16407 [ukb-d-7436 ukb-b-16407 [ukb-d-7436	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389		OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.513 (0.992 to 1.4 1.996 (0.970 to 1.2 1.514 (1.269 to 1.8 1.421 (1.195 to 1.6 1.005 (1.003 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0 1.070 (1.044 to 1.3 1.770 (1.044 to 1.3	pval 236) 0.231 236) 0.200 497) 0.060 238) 0.139 318) 0.000 3590 0.000 312) 0.000 307) 0.000 315) 0.000 310) 0.007	(F) study leg fat present to CHD ukb-a-274   ukb-d-I9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-7436 ukb-a-278   ieu-a-6 ukb-a-278   ieu-a-6 ukb-a-278   ukb-d-1668 ukb-a-278   ukb-b-1668 ukb-a-278   ukb-b-7436 ukb-a-278   ukb-b-1668	nsnp 251 129 77 249 243 251 248 126 68 250 243 252		DR (95 1.023 (1 - 1.738 (1 - 1.738 (1 - 1.720 (1 1.022 (1 1.377 (1 - 1.679 (1 1.0550 (1 1.022 (1 1.022 (1 1.022 (1 1.024 (1)	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.041 1.017 to 1.029 1.139 to 1.665 1.260 to 2.2352 1.016 to 1.027 1.008 to 1.015 1.008 to 1.030	P 9) 0 7) 0 2) 0 7) 0 2) 0 4) 0 5) 0 5) 0 7) 0 5) 0 7) 0 5) 0 0 7) 0 7) 0 7 7) 0 7) 0 7) 0 7) 0 7 7) 0 7 7) 0 7 7 7 7 7 7 7 7 7 7 7 7 7
Nudy arm fat precent to CHD   ner     hub a-282   finn-b-19_CHD   233     kb-a-282   finn-b-19_CHD   233     kb-a-282   ub-a-6   125     kb-a-282   ub-b-7436   233     kb-a-282   ub-b-7436   236     kb-a-282   ub-b-7436   236     kb-a-286   ub-b-1668   125     kb-a-286   ub-b-7436   236     kb-a-286   ub-b-7436   236     kb-a-286   ub-b-1668   256     kb-a-286   ub-b-17436   256     kb-a-286   ub-b-17436   256     kb-a-286   ub-b-17436   256     kb-a-286   ub-b-19264   266     kb-a-286   ub-b-19264   266     kb-a-286   ub-b-19264   266     kb-a-286   ub-b-19264   266     kb-b-12854   1m-b-19_CHD   267     kb-b-12854   1m-a-6   210		96 OR (95% CI) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.044 to 1.0 1.826 (1.044 to 1.5 1.822 (1.431 to 2.2 1.015 (1.010 to 1.0 1.008 (1.005 to 1.0 1.019 (1.014 to 1.0 1.386 (1.243 to 2.2 1.852 (1.431 to 2.2 1.852 (1.431 to 2.2 1.95 (1.243 to 2.2 1.95 (1.245 to 2.2) (1.2	pval 67) 0.001 44) 0.000 19) 0.000 19) 0.000 10) 0.000 20) 0.000 20) 0.000 20) 0.000 20) 0.000 20) 0.000 23) 0.000 07) 0.000 23) 0.000	(E) study trunk fat precent to C1 ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   inn-b-19_CH ukb-b-16407   inn-b-19_CH ukb-b-16407   iukb-b-1688 ukb-b-16407   ukb-b-7436 ukb-b-16407   ukb-b-7436 ukb-b-16407   ukb-d-19_CH Fixed effect model Random effect model	HD nsnp 0 235 123 74 HD 380 200 117 383 371 HD 389 0	.941	OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.421 (1.195 to 1.6 1.009 (1.003 to 1.0 1.011 (1.008 to 1.0 1.017 (1.005 to 1.0 1.077 (1.044 to 1.3 1.97	pval 236) 0.231 226) 0.000 497) 0.060 238) 0.139 318) 0.000 3500 0.000 307) 0.000 3100 0.007 310) 0.007	(F) study lag fat precent to CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=b-1688 ukb=a-274   ukb=b-1688 ukb=a-278   ukb=b-19_CHD ukb=a-278   ieu-a-6 ukb=a-278   ieu-a-9 ukb=a-278   ieu-a-9 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-17436 ukb=a-278   ukb=b-17436	nsnp 251 129 77 249 243 251 248 126 68 250 243 252 2422		DR (95' 1.023 (1 - 1.738 (1 - 1.720 (1 1.022 (1 1.011 (1 1.023 (1 1.023 (1 1.022 (1 1.024 (1 1.025 (1 1.0	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.322 1.016 to 1.027 1.008 to 1.027 1.008 to 1.027 1.139 to 1.665 1.260 to 2.235 1.489 to 2.552 1.496 to 2.552 1.016 to 1.027 1.008 to 1.015 1.016 to 1.027 1.008 to 1.015 1.412 to 1.482 1.42 to 1.482	P 9) 0 7) 0 2) 0 7) 0 1) 0 5) 0 5) 0 5) 0 7) 0 7) 0 7) 0 2) 0 7) 0 2) 0 7) 0 2) 0 0 2) 0 0 1) 0 2) 0 0 1) 0 1) 0 1
Nudy arm fat precent to CHD   psr     hudy arm fat precent to CHD   psr     kb-a-282   ieu-a-6   122     kb-a-282   ieu-a-6   122     kb-a-282   ieu-a-6   125     kb-a-282   ieu-a-6   233     kb-a-282   ieu-b-7436   233     kb-a-286   ieu-a-6   133     kb-a-286   ieu-a-6   136     kb-a-286   ieu-a-6   136     kb-a-286   ieu-b-7436   256     kb-a-286   ieu-b-7436   256     kb-a-286   ieu-b-7436   256     kb-a-286   ieu-b-7436   256     kb-a-284   iau-b-7436   256     kb-b-12854   iau-a-9   260     kb-b-12854   ieu-a-9   106     kb-b-12854   ieu-a-9   106		OR (95% CI) 1.340 (1131 to 1.5 - 1.898 (1.475 to 2.4 1.663 (1.321 to 2.0 1.014 (1.009 to 1.0 1.007 (1.004 to 1.0 1.027 (1.004 to 1.5 1.822 (1.431 to 2.3 1.536 (1.229 to 1.9 1.015 (1.101 to 1.0 1.015 (1.101 to 1.0 1.019 (1.014 to 1.0 1.398 (1.215 to 1.6 1.852 (1.433 to 2.2 1.673 (1.365 to 2.0	pval 67) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.000 20) 0.000 10) 0.0000 10) 0.0000 10) 0.0000 10) 0.0000 10) 0.0000 10) 0.00000 10) 0.0000 10) 0.0000 10) 0.0	(E) study trunk fat precent to C1 ukb-a-290   ieu-a-6 ukb-a-290   ieu-a-6 ukb-b-16407   inu-b-19_C1 ukb-b-16407   ieu-a-6 ukb-b-16407   iukb-b-7668 ukb-b-16407   iukb-b-7668 ukb-b-16407   iukb-b-7656 kb-b-16407   iukb-b-7656 kb-b-16407   iukb-b-7656 kb-b-16407   iukb-b-7656	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389	9	OR (95% Cl) 1.084 (0.950 to 1.2 → 1.553 (1.253 to 1.9 - 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 → 1.519 (1.269 to 1.8 - 1.421 (1.195 to 1.6 1.005 (1.003 to 1.0 1.001 (1.008 to 1.0 1.007 (1.005 to 1.0 1.077 (1.044 to 1.3 1.97	pval     2263   0.231     264   0.231     265   0.231     268   0.139     3180   0.000     3900   0.000     3912   0.000     3015   0.000     3015   0.000     3016   0.000	(F) study leg fat precent to CHD ukb-a-274   ukb-d-I9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-168 ukb-a-274   ukb-b-1688 ukb-a-274   ukb-b-7436 ukb-a-278   ieu-a-9 ukb-a-278   ieu-a-9 ukb-a-278   ukb-b-1688 ukb-a-278   ukb-b-1688 ukb-a-278   ukb-b-1688 ukb-a-278   ukb-b-1688 ukb-a-278   ukb-b-1688	nsnp 251 129 243 251 248 251 248 126 68 250 243 250 243 252 422 231		OR (95' 1.023 (1 - 1.738 (1 1.728 (1 1.722 (1 1.021 (1 1.023 (1 1.021 (1 1.071 (1 1.679 (1 1.679 (1 1.679 (1 1.022 (1 1.025 (1) (1) (1 1.025 (1) (1) (1 1.025 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.036 to 1.047 1.017 to 1.029 1.138 to 1.025 1.488 to 2.552 1.016 to 1.027 1.016 to 1.030 1.142 to 1.482 1.326 to 1.4182 1.326 to 1.3182 1.326 to 1.326 to 1.32	
Vandom effect model     budy arm fat precent to CHD   nsr     budy arm fat precent to CHD   237     bbra-282   film-b-19_CHD   237     bbra-282   film-b-1868   235     bbra-282   film-b-1436   233     bbra-282   film-b-17436   235     bbra-286   film-b-19_CHD   255     bbra-286   film-b-1688   256     bbra-286   film-b-19_CHD   255     bbra-286   film-b-19_CHD   256     bbra-286   film-b-19_CHD   266     bbra-286   film-b-19_CHD   266     bbra-286   film-b-19_CHD   266     bbra-286   film-b-19_CHD   261     bbra-286   tub-b-18254   film-a-9   106     bbra-12854   film-a-9   106     bbra-12854   tub-b-1868   386     bbra-12854   tub-b-1868   386		96 OR (95% CI) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.041 (1.006 to 1.0 1.027 (1.004 to 1.5 1.822 (1.431 to 2.3 1.536 (1.229 to 1.9 1.015 (1.010 to 1.0 1.006 (1.005 to 1.0 1.006 (1.005 to 1.0 1.396 (1.215 to 1.6 1.852 (1.433 to 2.2 1.673 (1.365 to 2.0 1.016 (1.012 to 1.0) 0.106 (1.012 to 1.0)	pval 67 0.001 44) 0.000 93) 0.000 10) 0.000 10) 0.000 20) 0.000 20) 0.000 10) 0.000 10) 0.000 23) 0.000 10) 0.000 98) 0.000 98) 0.000 99. 0.000 90. 0.0000 90. 0.0000 90. 0.0000 90. 0.0000 90. 0.0000 90. 0.0000	(E) study trunk fat precent to C1 ukb-a-290 [inn-b-19_CHD ukb-a-290 [ieu-a-6 ukb-b-16407 [inn-b-19_CH ukb-b-16407 [inn-b-19_CH ukb-b-16407 [inn-b-19_CH ukb-b-16407 [ukb-b-1688 ukb-b-16407 [ukb-d-19_CH Fixed effect model	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389 0		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.553 (1.253 to 1.9 1.519 (1.0992 to 1.4 1.966 (0.970 to 1.2 1.421 (1.195 to 1.6 1.009 (1.005 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0 1.017 (1.005 to 1.0 1.170 (1.044 to 1.3 1.97	<b>pval</b> 236) 0.231 326) 0.000 497) 0.060 338) 0.139 318) 0.000 950) 0.000 015) 0.000 015) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-1668 ukb-a-276   ukb-d-19_CHD ukb-a-278   ukb-d-19_CHD ukb-a-278   ukb-d-1668 ukb-a-278   ukb-d-19_CHD ukb-b-7212   inn-b-19_CHD ukb-b-7212   inn-a-19_CHD ukb-b-7212   inn-a-19_CHD	nsnp 251 129 77 249 243 251 248 126 68 250 243 252 243 252 422 231 108		1.96 OR (95' 1.022 (1 1.738 (1 1.720 (1 1.022 (1 1.072 (1 1.075 (1 1	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.016 to 1.027 1.260 to 2.235 1.260 to 2.235 1.4616 to 1.027 1.016 to 1.027 1.016 to 1.027 1.016 to 1.027 1.016 to 1.027 1.016 to 1.037 1.016 to 1.037 1.016 to 1.037 1.240 to 1.452 1.246 to 1.915 1.246	F (7) 0 (7) 0
Andom effect model tudy arm fat precent to CHD nsr kb-a-282   finn-b-19_CHD 237 kb-a-282   ieu-a-6 122 kb-a-282   ieu-a-9 75 kb-a-282   uk-b-b-1668 233 kb-a-286   ieu-a-9 75 kb-a-286   ieu-a-9 80 kb-a-286   ieu-a-9 80 kb-a-286   uk-b-b-1688 255 kb-a-286   uk-b-b-1686 395 kb-a-286   uk-b-19_CHD 265 kb-a-286   uk-b-19_CHD 265 kb-a-286   uk-b-19_CHD 387 kb-b-12854   ieu-a-9 105 kb-b-12854   ieu-a-9 105 kb-b-12854   ieu-a-9 105 kb-b-12854   ieu-a-9 105 kb-b-12854   ieu-a-9 37 kb-b-12854   ieu-a-9 37		OR (95% CI) 1.340 (1.131 to 1.5 - 1.996 (1.475 to 2.4 1.663 (1.321 to 2.0 1.007 (1.004 to 1.0 1.007 (1.004 to 1.0 1.007 (1.004 to 1.0 1.265 (1.009 to 1.0 1.026 (1.009 to 1.0 1.026 (1.004 to 1.0 1.036 (1.005 to 1.0 1.019 (1.014 to 1.0 1.019 (1.015 to 2.0 1.016 (1.012 to 1.0 0.006 (1.012 to 1.0 0.006 (1.012 to 1.0)	pval 77) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.000 20) 0.000 20) 0.000 23) 0.000 23) 0.000 23) 0.000 23) 0.000 23) 0.000 20) 0.0000 20) 0.0000 20) 0.0000 20) 0.0000 20) 0.0000 20) 0.00000 20) 0.0000 20) 0.00	(E) study trunk fat precent to C1 ukb-a-290   ieu-a-6 ukb-a-290   ieu-a-6 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-6 ukb-b-16407   ieu-a-9 ukb-b-16407   ukb-b-1643 ukb-b-16407   ukb-b-7436 ukb-b-16407   ukb-d07   ukb- Fixed effect model Random effect model	HD nsnp 0 235 123 74 HD 380 200 117 383 371 HD 389 0	9 	OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.424 (1.195 to 1.6 1.009 (1.005 to 1.0 1.017 (1.008 to 1.0 1.077 (1.005 to 1.0 1.170 (1.044 to 1.3 1.97	<b>pval</b> 236) 0.231 326) 0.000 497) 0.060 336) 0.139 318) 0.000 300) 0.000 172) 0.000 307) 0.000 175) 0.000 175) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb-a-274   ukb-d-l9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-9 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-9_CHD ukb-a-278   ieu-a-9 ukb-a-278   ieu-a-9 ukb-a-278   ukb-b-1668 ukb-a-278   ukb-b-1668 ukb-a-278   ukb-b-7436 ukb-a-278   ukb-b-7436 ukb-a-2721   ueu-a-6 ukb-b-7212   ueu-a-6	nsnp 251 129 77 249 243 251 248 126 68 250 243 252 422 231 108 414		1.96 OR (95 1.023 (1 - 17.28 (1 - 17.28 (1 - 17.20 (1 1.022	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.036 to 1.027 1.136 to 1.042 1.136 to 1.045 1.1489 to 2.552 1.016 to 1.027 1.016 to 1.027 1.016 to 1.027 1.016 to 1.027 1.136 to 1.030 1.142 to 1.4622 1.296 to 1.915 1.198 to 1.773 1.016 to 1.077 1.016	P (7) 0 (7) 0
Nudy arm fat precent to CHD   nsr     budy arm fat precent to CHD   nsr     bb-a-282 [inn-b-l9_CHD   233     bb-a-282 [inu-a-6   122     bb-a-282 [inu-a-6   123     bb-a-282 [inu-a-6   123     bb-a-282 [inu-a-6   123     bb-a-286 [inu-a-6   133     bb-a-286 [inu-a-6   133     bb-a-286 [inu-a-6   133     bb-a-286 [inu-b-17436   255     bb-a-286 [inu-b-1854   210     bb-12854 [inu-b-186   365     bb-12854 [inu-b-17438   376     bb-12854 [inb-b-17438   376     bb-12854 [inb-b-17438   376     bb-12854 [inb-b-17438   376     bb-12854 [inb-b-17438   376		0R (95% CI) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.025 (1.094 to 1.5 1.822 (1.431 to 2.3 1.015 (1.010 to 1.0 1.016 (1.010 to 1.0 1.019 (1.04 to 1.0 1.019 (1.04 to 1.0 1.019 (1.010 to 1.0 1.016 (1.012 to 1.0 1.016 (1.014 to 1.0)	pval pval 44) 0.000 93) 0.001 94) 0.000 10) 0.000 20) 0.000 10) 0.000 20) 0.000 10) 0.000 23) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 20) 0.0000 20) 0.0000 20) 0.0000 20) 0.0000 20) 0.00000 20)	(E) study trunk fat precent to Cl ukb-a-290 [sin-b-19_CHD ukb-a-290 [sin-a-6 ukb-b-290 [sin-a-9 ukb-b-16407 [sin-a-9] ukb-b-16407 [sin-a-9] ukb-b-16407 [sin-a-6] ukb-b-16407 [ukb-b-7436 ukb-b-16407 [ukb-d-19_CH Fixed effect model	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389 0		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.553 (1.253 to 1.9 1.996 (0.970 to 1.2 1.096 (0.970 to 1.2 1.1519 (1.269 to 1.8 1.009 (1.005 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0 1.017 (1.004 to 1.3 1.97	pval     2236)   0.231     2260)   0.000     977)   0.600     238)   0.139     3180)   0.000     3900)   0.000     3907)   0.000     3107)   0.000     310)   0.007	(F) study leg fat precent to CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-274   ukb=d-19_CHD ukb=a-278   ukb=d-19_CHD ukb=a-278   ukb=d-19_CHD ukb=a-278   ukb=d-1668 ukb=a-278   ukb=d-1668 ukb=a-278   ukb=d-1668 ukb=a-278   ukb=d-1668 ukb=a-278   ukb=d-1668 ukb=a-2721   ukb=d-19_CHD ukb=b-7212   ukb=d-19_CHD ukb=b-7212   ukb=d-1648 ukb=b-7212   ukb=d-1648 ukb=b-7212   ukb=d-1648 ukb=b-7212   ukb=d-1648	nsnp 251 129 77 243 251 243 251 248 126 68 250 243 250 243 252 422 231 108 414 405		1.96 <b>DR (95%</b> 1.023 (1 1.728 (1	% CI) 1.017 to 1.029 1.327 to 2.277, 1.326 to 2.232, 1.016 to 1.027, 1.139 to 1.029, 1.139 to 1.029, 1.139 to 1.029, 1.489 to 2.552; 1.016 to 1.025, 1.016 to 1.027, 1.016 to 1.029, 1.142 to 1.4822, 1.296 to 1.713, 1.016 to 1.027, 1.096 to 1.027, 1.016 to 1.027,	F (1) 0 (1) 0
Andom effect model tudy arm fat precent to CHD nsr kb-a-282   finn-b-19_CHD 233 kb-a-282   ieu-a-6 125 kb-a-282   ieu-a-6 125 kb-a-282   ukb-b-1688 233 kb-a-282   ukb-b-1688 235 kb-a-286   ieu-a-6 830 kb-a-286   ieu-a-6 830 kb-a-286   ukb-b-1686 838 kb-a-286   ukb-b-19_CHD 265 kb-a-286   ukb-b-19_CHD 265 kb-b-12854   ukb-b-19_CH3 376 kb-b-12854   ukb-b-1686 386 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-149_CH3 387 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-149_CH3 387 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1483 377 kb-b-12854   ukb-b-1683 387 kb-b-12854   ukb-b-1683 387 kb-b-12854   ukb-b-1683 387 kb-b-12854   ukb-b-1683 387 kb-b-12854   ukb-b-1683 387 kb-b-12854   ukb-b-1684 387 kb-b-12854   ukb-b-1683 387 kb-b-12854   ukb-b-1685 kb-b-1683 387		96 0R (95% CI) 1.340 (1.131 to 1.5 -1.898 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.004 to 1.0 1.025 (1.030 to 1.0 1.025 (1.030 to 1.0 1.055 (1.020 to 1.0 1.056 (1.020 to 1.0 1.398 (1.215 to 1.6 1.852 (1.430 to 2.2 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0 1.016 (1.014 to 1.0 1.016 (1.012 to 1.0 1.016 (1.014 to 1.0 1.016 (1.012 to 1.0 1.016 (1.014 to 1.0 1.016 (1.014 to 1.0 1.016 (1.014 to 1.0 1.016 (1.012 to 1.0 1.038 (1.210 to 1.6 1.339 (1.210 to 1.6) 1.339 (1.210 to 1.6) 1.33	pval (7) 0.001 (4) 0.000 (93) 0.000 (19) 0.000 (10) 0.000 (1	(E) study trunk fat precent to C1 ukb-a-290   finn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   inn-b-19_CH ukb-b-16407   inn-b-19_CH ukb-b-16407   iuk-b-1688 ukb-b-16407   iukb-b-7438 ukb-b-16407   iukb-b-7438 ukb-b-16407   iukb-d-19_CH Fixed effect model Random effect model	HD nsng 235 123 74 HD 380 200 117 383 371 HD 389 0	9	OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.421 (1.195 to 1.6 1.009 (1.005 to 1.0 1.007 (1.005 to 1.0 1.077 (1.005 to 1.0 1.770 (1.044 to 1.3 1.97	<b>pval</b> 236) 0.231 326) 0.000 497) 0.060 497) 0.060 497) 0.000 490) 0.000 112) 0.000 112) 0.000 112) 0.000 115) 0.000 115) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-274   ukb=d=0_CHD ukb=a-278   ukb=d=0_CHD ukb=a-278   ukb=d=0_CHD ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1668	nsnp 251 129 77 249 251 248 126 68 250 243 250 243 250 243 252 422 231 108 414 405		1.96 OR (95* 10.22 (1 - 1.728 (1 - 1.728 (1 - 1.728 (1 1.022 (1 1.021	% CI) 1.017 to 1.029 1.327 to 2.277, 1.326 to 2.232 1.016 to 1.027, 1.038 to 1.014, 1.017 to 1.029 1.139 to 1.044, 1.028 to 2.552; 1.018 to 1.030, 1.038 to 1.030, 1.142 to 1.442, 1.296 to 1.915; 1.99 to 1.915, 1.919 to 1.030, 1.1910 to 1.017, 1.010 to 1.017, 1.010 to 1.017, 1.010 to 1.017, 1.010 to 1.017, 1.010 to 1.017, 1.011 to 1.019, 1.011 to 1.011, 1.011 to 1.011, 1.	P () () () () () () () () () ()
Andom effect model tudy arm fat precent to CHD psr kbra-262   finn-b-19_CHD 237 kbra-262   eu-a=6 122 kbra-282   eu-a=9 75 kbra-282   eu-a=9 75 kbra-282   uk-b-7436 233 kbra-286   uk-b-1668 235 kbra-286   uk-b-6168 255 kbra-286   uk-b-6168 255 kbra-286   uk-b-7436 255 kbra-284   uk-b-7436 255 kbra-284   uk-b-7436 375 kbra-12854   uk-b		0R (95% CI) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.285 (1.094 to 1.5 1.822 (1.431 to 2.3 1.636 (1.229 to 1.9 1.015 (1.010 to 1.0 1.019 (1.010 to 1.0 1.016 (1.012 to 1.0 1.018 (1.014 to 1.0 1.018 (1.014 to 1.0 1.399 (1.210 to 1.6 1.399 (1.210 to 1.6) 1.399 (1.	pval 67) 0.001 44) 0.000 19) 0.000 10) 0.000 10) 0.000 20) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 11) 0.000 23) 0.000 11) 0.000 23) 0.000 11) 0.000 23) 0.000 25) 0.000 25) 0.000 25) 0.000 25) 0.000 25) 0.000 25) 0.000 25) 0.000 25) 0.0000 25) 0.000 25) 0.000 25) 0.000 25) 0.000 25) 0.000 25)	(E) study trunk fat precent to CI ukb-a-290 [inu-b-19_CHD ukb-a-290 [inu-a-6 ukb-b-200 [inu-a-9 ukb-b-16407 [inu-a-9] ukb-b-16407 [inu-a-9] ukb-b-16407 [inu-a-6] ukb-b-16407 [inu-b-7436 ukb-b-16407 [ukb-d-19_CF Fixed effect model	HD nsnp 0 235 123 74 HD 380 200 117 383 371 HD 389 0	9	OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.513 (0.992 to 1.4 1.966 (0.970 to 1.2 1.519 (1.269 to 1.6 1.009 (1.005 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0 1.017 (1.055 to 1.0 1.07 (1.055 to 1.0 1.170 (1.044 to 1.3 1.97	pval     2236)   0.231     326)   0.000     977)   0.600     318)   0.000     318)   0.000     312)   0.000     312)   0.000     315)   0.000     316)   0.000     310)   0.007	(F) study leg fat precent to CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688	nsnp 251 129 77 249 243 251 248 126 68 250 243 252 422 231 108 414 405 424 0 379		1.96 OR (95% 1.23 (1 1.728 (1 1.	% CI) 1.017 to 1.029 1.327 to 2.277, 1.325 to 2.232, 1.016 to 1.027, 1.026 to 1.027, 1.026 to 1.027, 1.026 to 1.027, 1.026 to 1.029, 1.260 to 2.235, 1.260 to 2.522, 1.016 to 1.027, 1.016 to 1.027, 1.016 to 1.027, 1.026 to 1.015, 1.199 to 1.773, 0.0105 to 1.009, 0.016 to 1.017, 0.016 to 1.027, 0.016 to 1.027, 1.026 to 1.016, 1.026 to 1.019, 0.016 to 1.027, 0.016 to 1.027,	P () () () () () () () () () ()
Andom effect model tudy arm fat precent to CHD nsr hts-a-282   finn-b-19_CHD 233 kb-a-282   ieu-a-6 125 kb-a-282   ieu-a-6 125 kb-a-282   ieu-a-6 125 kb-a-282   ieu-b-1688 235 kb-a-286   ieu-a-6 135 kb-a-286   ieu-a-6 135 kb-b-12854   ieu-a-6 216 kb-b-12854   ieu-a-9 100 kb-b-12854   ieu-a-9 100 kb-b-12854   ukb-b-1436 376 kb-b-12854   ukb-b-7436 376 kb-b-12854   ukb-b-1436 376 kb-b-12854   ukb-b-1436 376 kb-b-12854   ukb-b-1436 376 kb-b-12854   ukb-b-1436 376 kb-b-12018   ieu-a-9 110 kb-b-12854   ukb-b-1436 376 kb-b-12018   ieu-a-9 110 kb-b-1854   ukb-b-185 kb-b-20188   ieu-a-9 110 kb-b-185 kb-b-20188   ieu-a-9 110 kb-b-185 kb-b-20188   ieu-a-9 110 kb-b-185 kb-b-20188   ieu-a-9 110 kb-b-185 kb-b-20188   ieu-a-9 110 kb-b-185 kb-b-2018   ieu-a-9 110 kb-b-185 kb-b-2018 kb-b-2018 kb-b-185 kb		96 0R (95% CI) 1.340 (1.131 to 15. - 1.896 (1.475 to 24. 1.663 (1.322 to 24. 1.663 (1.322 to 24. 1.663 (1.322 to 24. 1.663 (1.322 to 24. 1.014 (1.009 to 10. 1.027 (1.044 to 10. 1.326 (1.044 to 10. 1.326 (1.044 to 10. 1.396 (1.252 to 14. 1.352 (1.431 to 22. 1.673 (1.365 to 24. 1.365 (1.243 to 22. 1.673 (1.365 to 24. 1.016 (1.014 to 10. 1.016 (1.014 to 10. 1.036 (1.006 to 10. 1.036 (1.021 to 16. 1.395 (1.527 to 23. 1.766 (1.377 to 23.	pval (87) 0.001 (44) 0.000 (93) 0.000 (19) 0.000 (10) 0.000 (20) 0.000	(E) study trunk fat precent to Cl ukb-a-290 [imn-b-19_CHD ukb-a-290 [ieu-a-6 ukb-b-16407 [imu-a-9 ukb-b-16407 [imu-a-9 ukb-b-16407 [imu-a-9 ukb-b-16407 [ukb-b-1688 ukb-b-16407 [ukb-b-7436 ukb-b-16407 [ukb-b-7436 ukb-b-16407 [ukb-d-19_Ch Fixed effect model Random effect model	HD nsnp ) 235 123 74 HD 380 200 117 383 371 14D 389 0		OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.421 (1.195 to 1.6 1.009 (1.003 to 1.0 1.007 (1.005 to 1.0 1.007 (1.005 to 1.0 1.077 (1.044 to 1.3 1.97	<b>pval</b> 236) 0.231 326) 0.000 497) 0.060 238) 0.139 418) 0.000 900) 0.000 112) 0.000 112) 0.000 112) 0.000 115) 0.000 308) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=d-19_CHD ukb=a-274   ukb=b-1688 ukb=a-274   ukb=b-1688 ukb=a-274   ukb=b-1688 ukb=a-278   iukb=b-1688 ukb=a-278   iukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=b-7212   iukb=b-1688 ukb=b-7212   iukb=b-1688 ukb=b-7212   iukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7312   iukb=b-1688 ukb=b-7312   iukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7312   ukb=b-1688 ukb=b-7313   ukb=d-19_CHD ukb=b-18377   imn=b=0_CHD	nsnp 251 129 77 249 243 251 248 126 68 243 250 243 252 422 231 108 414 405 424 0 379 209		1.96 OR (95° 1.023 (1 1.738 (1 1.738 (1 1.728 (1 1.022 (1 1.025 (1 1.055 (1 1	% CI) 1.017 to 1.029 1.327 to 2.277, 1.326 to 2.232 1.016 to 1.027, 1.036 to 1.027, 1.036 to 1.047, 1.036 to 1.045, 1.036 to 1.045, 1.016 to 1.037, 1.016 to 1.037, 1	F   3) 0   7) 0
Andom effect model		0R (95% Cl) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.265 (1.044 to 1.0 1.265 (1.044 to 1.0 1.363 (1.223 to 1.9 1.015 (1.016 to 1.0 1.019 (1.016 to 1.0 1.019 (1.016 to 1.0 1.018 (1.016 to 1.0 1.018 (1.016 to 1.0 1.018 (1.014 to 1.0 1.399 (1.275 to 1.6 1.399 (1.275 to 1.6 1.395 (1.275 to 2.3 1.706 (1.397 to 2.0 1.016 (1.0172 to 1.0) 1.016 (1.0172 to 1.0)	pval 67) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.000 20) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 10) 0.000 11) 0.000 23) 0.000 11) 0.000 23) 0.000 11) 0.000 23) 0.000 11) 0.000 23) 0.000 11) 0.000 23) 0.000 20) 0	(E) study trunk fat precent to C1 ukb-a-290   inn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-6 ukb-b-16407   iukb-d-182 ukb-b-16407   iukb-d-182 ukb-b-16407   iukb-d-182 hkb-b-16407   iukb-d-1	HD nsnp 235 123 74 HD 200 117 383 371 HD 389 0	9	OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.553 (1.255 to 1.9 1.553 (1.255 to 1.6 1.096 (0.970 to 1.2 1.010 (1.269 to 1.6 1.006 (1.005 to 1.0 1.005 (1.005 to 1.0 1.011 (1.008 to 1.0 1.017 (1.005 to 1.0 1.07 (1.005 to 1.0 1.170 (1.044 to 1.3 1.97	<b>pval</b> 236) 0.231 326) 0.000 497) 0.060 338) 0.139 3180 0.000 5300 0.000 5300 0.000 515) 0.000 0.050 0.000 310) 0.007	(F) study leg fat precent to CHD ukb-a-274   ukb-d-19_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-d-19_CHD ukb-a-278   ieu-a-6 ukb-a-278   ieu-a-6 ukb-a-278   ukb-d-16_CHD ukb-a-278   ukb-d-16_CHD ukb-a-278   ukb-d-16_CHD ukb-a-278   ukb-d-16_CHD ukb-b-7212   ukb-d-16_CHD ukb-b-7212   ieu-a-6 ukb-b-7212   ieu-a-6 ukb-b-7212   ukb-d-1668 ukb-b-7212   ukb-d-1668 ukb-b-7212   ukb-d-16_CHD ukb-b-7377   ieu-a-6 ukb-b-7377   ieu-a-9	nsnp 251 129 249 243 251 126 68 250 243 252 422 243 255 243 255 243 255 243 255 243 255 243 255 243 250 243 251 108 414 405 201 109 201 109 201 109 201 109 201 201 201 201 201 201 201 201 201 201		1.96 OR (95% 1.023 (1 1.728 (1 1.728 (1 1.728 (1 1.728 (1 1.728 (1 1.728 (1 1.728 (1 1.728 (1 1.011 (1 1.011 (1 1.027 (1 1.022 (1 1.012 (1 1.022 (1 1.025 (1 1	% CI) 1.017 to 1.029 1.322 to 2.277, 1.325 to 2.232, 1.326 to 2.232, 1.016 to 1.027, 1.008 to 1.014, 1.017 to 1.029, 1.480 to 2.2552, 1.016 to 1.027, 1.018 to 1.030, 1.142 to 1.482, 1.296 to 1.915, 1.196 to 1.773, 1.010 to 1.077, 1.010 to 1.077, 1.010 to 1.079, 1.014 to 1.039, 1.344 to 1.904, 1.584 to 2.688, 1.584 to 2.584,	F (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)
Nudy arm fat precent to CHD   ner     hub a-282   finn-b-19_CHD   233     kb-a-282   ieu-a-6   125     kb-a-286   ieu-a-6   135     kb-a-286   ieu-a-6   135     kb-a-286   ieu-a-6   135     kb-a-286   ieu-a-9   80     kb-a-286   ieu-a-9   100     kb-a-286   ieu-a-9   100     kb-b-12854   ieu-a-9   101     kb-b-20188   ieu-a-9   110     kb-b-20188   ieu-a-9   110     kb-b-20188   ieu-a-9   110     kb-b-20188   ieu-b-1668   385     kb-b-20188   ieu-b-1668   385     kb-b-20188   ieu-b-1668   385 <td< td=""><td></td><td>06 (95% C) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.044 to 1.0 1.027 (1.044 to 1.0 1.026 (1.049 to 1.5 1.822 (1.431 to 2.2 1.015 (1.010 to 1.0 1.019 (1.014 to 1.0 1.096 (1.006 to 1.0 1.019 (1.014 to 1.0 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0 1.036 (1.527 to 2.3 1.076 (1.397 to 2.0 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0 1.056 (1.577 to 2.3 1.076 (1.397 to 2.0 1.016 (1.012 to 1.0 1.006 (1.002 to 1.0 1.006 (1.012 to 1.0) 1.006 (1.012 to 1.0 1.006 (1.012 to 1.0) 1.006 (1.012 to 1.0) 1</td><td>pval (a) 0.001 (b) 0.001 (c) 0.000 (c) 0</td><td>(E) study trunk fat precent to Cl ukb-a-290 [imn-b-19_CHD ukb-a-290 [ieu-a-6 ukb-b-16407 [imn-b-19_CH ukb-b-16407 [imn-b-19_CH ukb-b-16407 [ikb-b-1688 ukb-b-16407 [ukb-b-7438 ukb-b-16407 [ukb-d-19_CH Fixed effect model Random effect model</td><td>HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389 0</td><td>9</td><td>OR (95% Cl) 1.084 (0.950 to 1.2 - 1.553 (1.253 to 1.9 - 1.519 (0.992 to 1.4 1.096 (0.970 to 1.2 - 1.519 (1.269 to 1.8 - 1.421 (1.195 to 1.6 - 1.009 (1.003 to 1.0 1.007 (1.005 to 1.0 1.011 (1.008 to 1.0 - 1.070 (1.005 to 1.3 - 1.770 (1.044 to 1.3 - 1.97</td><td><b>pval</b> 236) 0.231 246) 0.000 497) 0.060 238) 0.139 318) 0.000 309) 0.000 312) 0.000 312) 0.000 315) 0.000 316) 0.000 310) 0.007</td><td>(F) study leg fat precent to CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=b-7212   iub=b-1668 ukb=b-7212   iub=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7377   iud=a-6 ukb=b-7377   iud=a-6 ukb=b-7377   iud=a-6 ukb=b-13377   iud=a-6 ukb=b-13377   iud=a-6 ukb=b-13377   ud=a-6 ukb=b-13377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-1688 ukb=b-18377   ud=b-1688 ukb=b-18377   ud=b-1688</td><td>nsnp 251 129 243 249 243 251 251 248 250 243 252 243 252 243 252 243 252 243 252 243 252 243 252 243 252 242 231 108 252 253 252 243 255 253 255 255 255 255 255 255 255 25</td><td></td><td>1.96 OR (95' 1.023 (1 1.728 (1</td><td>% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.237 1.326 to 2.237 1.326 to 1.027 1.326 to 1.027 1.326 to 1.027 1.326 to 1.027 1.326 to 1.025 1.488 to 2.552 1.016 to 1.075 1.016 to 1.075 1.016 to 1.077 1.096 to 1.019 1.016 to 1.077 1.096 to 1.019 1.016 to 1.077 1.036 to 1.041 1.584 to 2.625 1.584 to 2.625 1.524 t</td><td>P () () () () () () () () () ()</td></td<>		06 (95% C) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1.0 1.007 (1.044 to 1.0 1.027 (1.044 to 1.0 1.026 (1.049 to 1.5 1.822 (1.431 to 2.2 1.015 (1.010 to 1.0 1.019 (1.014 to 1.0 1.096 (1.006 to 1.0 1.019 (1.014 to 1.0 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0 1.036 (1.527 to 2.3 1.076 (1.397 to 2.0 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0 1.056 (1.577 to 2.3 1.076 (1.397 to 2.0 1.016 (1.012 to 1.0 1.006 (1.002 to 1.0 1.006 (1.012 to 1.0) 1.006 (1.012 to 1.0 1.006 (1.012 to 1.0) 1.006 (1.012 to 1.0) 1	pval (a) 0.001 (b) 0.001 (c) 0.000 (c) 0	(E) study trunk fat precent to Cl ukb-a-290 [imn-b-19_CHD ukb-a-290 [ieu-a-6 ukb-b-16407 [imn-b-19_CH ukb-b-16407 [imn-b-19_CH ukb-b-16407 [ikb-b-1688 ukb-b-16407 [ukb-b-7438 ukb-b-16407 [ukb-d-19_CH Fixed effect model Random effect model	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389 0	9	OR (95% Cl) 1.084 (0.950 to 1.2 - 1.553 (1.253 to 1.9 - 1.519 (0.992 to 1.4 1.096 (0.970 to 1.2 - 1.519 (1.269 to 1.8 - 1.421 (1.195 to 1.6 - 1.009 (1.003 to 1.0 1.007 (1.005 to 1.0 1.011 (1.008 to 1.0 - 1.070 (1.005 to 1.3 - 1.770 (1.044 to 1.3 - 1.97	<b>pval</b> 236) 0.231 246) 0.000 497) 0.060 238) 0.139 318) 0.000 309) 0.000 312) 0.000 312) 0.000 315) 0.000 316) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=d=19_CHD ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-274   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=a-278   ukb=b-1668 ukb=b-7212   iub=b-1668 ukb=b-7212   iub=b-1668 ukb=b-7212   ukb=b-1668 ukb=b-7212   ukb=b-1688 ukb=b-7212   ukb=b-1688 ukb=b-7377   iud=a-6 ukb=b-7377   iud=a-6 ukb=b-7377   iud=a-6 ukb=b-13377   iud=a-6 ukb=b-13377   iud=a-6 ukb=b-13377   ud=a-6 ukb=b-13377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-6 ukb=b-18377   ud=a-1688 ukb=b-18377   ud=b-1688 ukb=b-18377   ud=b-1688	nsnp 251 129 243 249 243 251 251 248 250 243 252 243 252 243 252 243 252 243 252 243 252 243 252 243 252 242 231 108 252 253 252 243 255 253 255 255 255 255 255 255 255 25		1.96 OR (95' 1.023 (1 1.728 (1	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.237 1.326 to 2.237 1.326 to 1.027 1.326 to 1.027 1.326 to 1.027 1.326 to 1.027 1.326 to 1.025 1.488 to 2.552 1.016 to 1.075 1.016 to 1.075 1.016 to 1.077 1.096 to 1.019 1.016 to 1.077 1.096 to 1.019 1.016 to 1.077 1.036 to 1.041 1.584 to 2.625 1.584 to 2.625 1.524 t	P () () () () () () () () () ()
Andom effect model		OR (95% CI) 1.340 (1.131 to 1.5 - 1.996 (1.131 to 1.5 - 1.998 (1.475 to 2.4 1.633 (1.321 to 2.0 1.007 (1.004 to 1.0 1.007 (1.004 to 1.0 1.025 (1.004 to 1.5 1.822 (1.431 to 2.3 1.536 (1.229 to 1.9 1.015 (1.101 to 1.0 1.019 (1.014 to 1.0 1.019 (1.014 to 1.0 1.019 (1.014 to 1.0 1.016 (1.012 to 1.0 1.006 (1.006 to 1.0 1.016 (1.012 to 1.0 1.006 (1.006 to 1.0 1.016 (1.012 to 1.0 1.006 (1.006 to 1.0 1.006 (1.006 to 1.0 1.016 (1.012 to 1.0 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0) 1.006 (1.006 to 1.0) 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0) 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0) 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0) 1.006 (1.006 to 1.0) 1.006 (1.006 to 1.0) 1.016 (1.012 to 1.0) 1.006 (1.006 to 1.0) 1.006 (1	pval (87) 0.001 44) 0.000 93) 0.000 19) 0.000 19) 0.000 10) 0.002 20) 0.000 20) 0.000 20) 0.000 20) 0.000 94) 0.000 94) 0.000 94) 0.000 94) 0.000 20) 0.000 11) 0.000 20) 0.000 51) 0.000 51) 0.000 20) 0.000 51) 0.000 20) 0.000 20]	(E) study trunk fat precent to C1 ukb-a-290   inn-b-19_CHD ukb-a-290   ieu-a-6 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-9 ukb-b-16407   ieu-a-6 ukb-b-16407   ieu-b-7436 ukb-b-16407   ieu-b-7436 ukb-b-16407   ieu-d-19_CF Fixed effect model Random effect model	HD nsng 235 123 74 HD 380 200 117 383 371 HD 389	9	OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.513 (0.992 to 1.4 1.996 (0.970 to 1.2 1.519 (1.269 to 1.8 1.421 (1.195 to 1.6 1.005 (1.005 to 1.0 1.005 (1.005 to 1.0 1.011 (1.008 to 1.0 1.071 (1.054 to 1.3 1.77	<b>pval</b> 236) 0.231 326) 0.000 197) 0.060 338) 0.139 318) 0.000 360) 0.000 307) 0.000 307) 0.000 315) 0.000 316) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb-a-274   ukb-d-I9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-7436 ukb-a-278   ieu-a-9 ukb-a-278   ieu-a-6 ukb-a-278   ieu-a-9 ukb-a-278   ukb-d-I9_CHD ukb-a-278   ukb-d-I9_CHD ukb-a-278   ukb-d-I9_CHD ukb-a-278   ukb-d-I9_CHD ukb-b-7212   ukb-b-1668 ukb-b-7212   ukb-b-1668 ukb-b-7212   ukb-b-1668 ukb-b-7377   inu-a-6 ukb-b-7377   inu-a-6 ukb-b-73377   inu-a-9 ukb-b-73377   ukb-b-16877   ukb-b-18377   ukb-18377   ukb-b-18377   ukb-18377   ukbb-18377   ukb-18377   ukb-18377   ukb-18377   ukb-18377   ukbb-1837	nsnp 251 129 77 249 243 251 248 250 248 250 243 252 422 252 422 301 108 414 405 424 20 9 209 209 101 377 377		1.96 OR (95' 1023 (1 1023 (1 1023 (1 1022 (1 1011 (1 1011 (1 1377 (1 1377 (1 1377 (1 1022 (1 1011 (1 1377 (1 1022 (1 1012 (1 1022 (1 1012 (1 1022 (1 1012 (1 1022 (1 1012 (1 1022 (1 1012 (1 1012 (1 1022 (1 1012 (1 10) (1 10) (1 10) (1 10) (1 10) (1 10) (1 10)	% CI) 1.017 to 1.029 1.327 to 2.277 1.327 to 2.277 1.326 to 2.232 1.016 to 1.027 1.008 to 1.047 1.017 to 1.029 1.139 to 1.655 1.260 to 2.2552 1.016 to 1.037 1.018 to 1.039 1.142 to 1.452 1.296 to 1.915 1.198 to 1.039 1.016 to 1.073 1.016 to 1.073 1.016 to 1.073 1.016 to 1.073 1.016 to 1.073 1.588 to 2.688 1.524 to 2.628 1.524 to 2.628 1.524 to 2.628 1.524 to 2.628 1.027 to 1.027 1.028 to 1.028 to 1.0	P () () () () () () () () () ()
Nudy arm fat precent to CHD   ner     htb-a-282   finn-b-19_CHD   237     hb-a-282   finn-b-19_CHD   237     hb-a-282   finn-b-19_CHD   237     hb-a-282   finn-b-1868   235     hb-a-282   finn-b-19_CHD   255     hb-a-288   finn-b-19_CHD   255     hb-a-286   finn-b-19_CHD   255     hb-a-286   finn-b-19_CHD   256     hb-a-286   finn-b-19_CHD   256     hb-a-286   lukb-b-1686   256     hb-a-286   lukb-b-19_CHD   266     hb-a-286   lukb-b-19_CHD   266     hb-a-286   lukb-b-19_CHD   366     hb-b-12854   lukb-b-1686   386     hb-b-12854   ukb-b-1686   386     hb-b-12854   ukb-b-168   386     hb-b-20188   ukb-b-168   386     hb-b-20188   ukb-b-168   386     hb-b-20188   ukb-b-1686   386		0R (95% CI) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.014 (1.009 to 1) 1.007 (1.004 to 1) 1.028 (1.094 to 1.5 1.822 (1.431 to 2.3 1.536 (1.229 to 1.9 1.015 (1.010 to 1) 1.006 (1.005 to 1.0 1.019 (1.014 to 1.0 1.036 (1.215 to 1.6 1.852 (1.431 to 2.2 1.673 (1.365 to 2.0 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0 1.393 (1.215 to 1.6 1.393 (1.215 to 1.6 1.395 (1.271 to 2.3 1.016 (1.012 to 1.0 1.016 (1.012 to 1.0) 1.016 (1.012 to 1.0) 1.01	pval 87) 0.001 44) 0.000 19) 0.000 19) 0.000 10) 0.002 20) 0.000 20) 0.000 20) 0.000 23) 0.000 23) 0.000 23) 0.000 23) 0.000 23) 0.000 23) 0.000 23) 0.000 51) 0.000 53) 0.0000 53) 0.000 53) 0.000 53) 0.000 53) 0.000 53) 0.000 53)	(E) study trunk fat precent to C1 ukb-a-290 [inn-b-19_CHD ukb-a-290 [ieu-a-6 ukb-b-16407 [inn-b-19_CH ukb-b-16407 [ieu-a-9 ukb-b-16407 [ieu-a-9 ukb-b-16407 [ieu-b-7436 ukb-b-16407 [ukb-d-19_CH Fixed effect model	HD nsnp 235 123 74 HD 380 200 117 383 371 HD 389 0	9	OR (95% Cl) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.9 1.553 (1.253 to 1.9 1.519 (1.0992 to 1.4 1.096 (0.970 to 1.2 1.424 (1.195 to 1.6 1.009 (1.005 to 1.0 1.005 (1.003 to 1.0 1.011 (1.008 to 1.0 1.017 (1.005 to 1.0 1.170 (1.044 to 1.3 1.97	pval     236)   0.231     326)   0.000     97)   0.600     318)   0.000     930)   0.000     930)   0.000     930)   0.000     931)   0.000     931)   0.000     931)   0.007	(F) study leg fat precent to CHD ukb-a-274   ukb-d-I9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-1668 ukb-a-278   ieu-a-6 ukb-a-278   ieu-a-6 ukb-a-278   ukb-d-19_CHD ukb-a-278   ukb-d-19_CHD ukb-b-7212   ieu-a-6 ukb-b-7212   ukb-d-19_CHD ukb-b-7212   ukb-d-19_CHD ukb-b-7212   ukb-d-19_CHD ukb-b-7212   ukb-d-19_CHD ukb-b-7371   ieu-a-6 ukb-b-7371   ieu-a-6 ukb-b-7371   ieu-a-6 ukb-b-7371   ieu-a-6 ukb-b-18377   ieu-a-6 ukb-b-18377   ieu-a-6 ukb-b-18377   ieu-a-6 ukb-b-18377   ieu-a-6 ukb-b-18377   ieu-a-6 ukb-b-18377   ieu-a-6 ukb-b-18377   ukb-b-1668	nsnp 251 129 243 243 245 252 252 252 252 252 252 252 252 252		1.96 OR (95% 1.023 (1 1.728 (1	% CI) 1.017 to 1.029 1.327 to 2.277 1.326 to 2.237 1.326 to 2.237 1.326 to 2.237 1.336 to 1.027 1.396 to 1.027 1.396 to 1.027 1.396 to 1.025 1.489 to 2.552 1.489 to 2.552 1.068 to 1.045 1.142 to 1.462 1.296 to 1.245 1.142 to 1.462 1.296 to 1.245 1.142 to 1.462 1.296 to 1.245 1.142 to 1.462 1.296 to 1.245 1.142 to 1.462 1.296 to 2.265 1.564 to 2.665 1.564 to 2.665 1.017 to 1.027 1.016 to 1.027 1.016 to 1.027 1.365 to 2.665 1.564 to 2.665 1.017 to 1.027 1.016 to 1.044 1.564 to 2.665 1.017 to 1.027 1.016 to 1.044 1.564 to 1.644 1.564 to 1.564 to 1.564 1.564 to 1.564 to 1.564 1.564 to 1.564	P 3) 0 2) 0 3)
Andom effect model () tudy arm fat precent to CHD nsr kb-a-282   inn-b-19_CHD 237 kb-a-282   ieu-a-6 122 kb-a-282   ieu-a-6 122 kb-a-282   ieu-a-9 75 kb-a-282   ieu-b-7436 233 kb-a-286   ieu-a-6 135 kb-a-286   ieu-a-6 135 kb-b-2854   ieu-a-9 80 kb-b-12854   ieu-a-9 80 kb-b-12854   ieu-a-9 80 kb-b-12854   ieu-a-9 105 kb-b-12854   ieu-a-9 20 kb-b-12854   ieu-a-9 20 kb-b-12854   ieu-a-9 20 kb-b-20188   ieu-a-6 213 kb-b-20188   ieu-a-6 213 kb-b-20188   ieu-a-9 105 kb-b-20188   ieu-a-9 20 kb-b-20188   ieu-a-0 20 kb-b-20188   ieu-		0R (95% CI) 1.340 (1.131 to 1.5 - 1.896 (1.475 to 2.4 1.663 (1.322 to 2.0 1.007 (1.004 to 1.0 1.007 (1.004 to 1.0 1.007 (1.004 to 1.0 1.025 (1.004 to 1.5 1.822 (1.431 to 2.2 1.536 (1.220 to 1.9 1.015 (1.101 to 1.0 1.019 (1.014 to 1.0 1.396 (1.220 to 1.9 1.396 (1.220 to 1.9 1.396 (1.215 to 1.6 1.395 (1.215 to 1.6 1.395 (1.215 to 1.6 1.395 (1.215 to 1.6 1.395 (1.210 to 1.0 1.395 (1.210 to 1.6 1.395 (1.210 to 1.6) 1.395 (1.21	pval 87) 0.001 44) 0.000 93) 0.000 19) 0.000 10) 0.000 20) 0.000 20) 0.000 20) 0.000 20) 0.000 20) 0.000 20) 0.000 20) 0.000 49) 0.000 20) 0.000 49) 0.000 20) 0.000 51) 0.000 51) 0.000 51) 0.000 20) 0.000 11) 0.000 22) 0.000 11) 0.000 22) 0.000 11) 0.000 22) 0.000 11) 0.000 22) 0.000 11) 0.000 22) 0.000 110 100 110 100 110 100 110 100 110 100 110 100	(E) study trunk fat precent to Cl ukb-a-290 [su-a-6 ukb-a-290 [su-a-6 ukb-b-16407 [su-a-9 ukb-b-16407 [su-a-9 ukb-b-16407 [su-a-6 ukb-b-16407 [ukb-b-1688 ukb-b-16407 [ukb-d-19_Cl Fixed effect model Random effect model	HD nsnp 9 235 123 74 HD 380 200 117 383 371 HD 389 0	9	OR (95% CI) 1.084 (0.950 to 1.2 1.553 (1.253 to 1.3 1.219 (0.992 to 1.4 1.096 (0.970 to 1.2 1.519 (1.269 to 1.8 1.421 (1.195 to 1.6 1.009 (1.005 to 1.0 1.007 (1.005 to 1.0 1.077 (1.005 to 1.0 1.770 (1.044 to 1.3 1.97	<b>pval</b> 236) 0.231 326) 0.000 197) 0.060 330) 0.339 380) 0.000 390) 0.000 307) 0.000 307) 0.000 307) 0.000 316) 0.000 310) 0.007	(F) study leg fat precent to CHD ukb-a-274   ukb-d-I9_CHD ukb-a-274   ieu-a-6 ukb-a-274   ieu-a-6 ukb-a-274   ukb-b-1668 ukb-a-274   ukb-b-7436 ukb-a-278   ieu-a-9 ukb-a-278   ieu-a-9 ukb-a-278   ieu-a-6 ukb-a-278   ukb-b-1668 ukb-a-278   ukb-b-7436 ukb-a-278   ukb-b-7436 ukb-a-278   ukb-b-7436 ukb-a-278   ukb-b-1668 ukb-b-7212   ukb-b-1668 ukb-b-7212   ukb-b-1668 ukb-b-7212   ukb-b-1668 ukb-b-7377   imu-a-6 ukb-b-7377   imu-a-9 ukb-b-7377   imu-a-9 ukb-b-73377   imu-a-9 ukb-b-73377   imu-a-9 ukb-b-73377   ukb-b-1688 ukb-b-18377   iub-b-1688 ukb-b-18377   ukb-b-7436 ukb-b-7337   ukb-b-7436	nsnp     251     129     77     243     251     243     251     243     251     243     251     243     252     243     252     243     252     243     252     243     252     243     252     243     252     243     252     243     252     231     108     414     405     405     405     209     101     377     368     2083		1.96 OR (95' 1023 (1 1023 (1 1023 (1 1022 (1 1011 (1 1011 (1 1377 (1 1377 (1 1377 (1 1377 (1 1377 (1 1377 (1 1377 (1 1377 (1 1377 (1 1012 (1 1377 (1 1012 (1 1377 (1 1012 (1 1377 (1 1012 (1 10) (1 10) (1 10) (1 10) (1 10) (1 10) (1 10)	% CI) 1.017 to 1.029 1.327 to 2.277, 1.327 to 2.277, 1.326 to 2.232, 1.016 to 1.027, 1.016 to 1.027, 1.016 to 1.027, 1.016 to 1.027, 1.016 to 1.027, 1.016 to 1.027, 1.016 to 1.019, 1.016 to 1.019, 1.016 to 1.019, 1.016 to 1.029, 1.016 to 1.029, 1.026 to 1.041, 1.5824 to 2.683, 1.5824 to 2.683, 1.026 to 1.041, 1.026 to 1.041, 1.026 to 1.041, 1.026 to 1.041, 1.026 to 1.041, 1.036 to 1.041,	P'     3)   0.     7)   0.     2)   0.     7)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     3)   0.     7)   0.     3)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.     5)   0.

2.76